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Abstract 
Alzheimer’s disease (AD) is a neurodegenerative pathology that becomes 
increasingly common with aging, characterized by extracellular accumulation of senile 
plaques (Aβ), intracellular appearance of neurofibrillary tangles and neuronal loss. 
 AD affects about 35 million people worldwide, and if current trends continue 
with no medical advancement, one in 85 people will be affected by 2050. Thus, there is 
an urgent need to develop a cost-effective, easy to use sensor platform to facilitate the 
diagnostic process, identify patients at an earlier stage and allow monitorization of 
biochemical effects of the treatments.  
Since the quantification of amyloid beta (Aβ) has been established as a reliable 
test to diagnose AD through human clinical trials, an electrochemical immunosensor 
was designed and developed for detection of this biomarker in biological fluids and is 
the focus of this work. It is based on a gold electrode modified with mercaptopropionic 
acid self-assembled monolayer, electrodeposited gold nanoparticles and Aβ antibody. 
Antibodies act as the biorecognition element of the sensor and selectively capture and 
bind Aβ42 to the electrode surface. The antibodies were immobilized on gold 
nanoparticles that offered excellent properties for electroanalytical assays. Cyclic and 
square-wave voltammetry, as well as electrochemical impedance spectroscopy were 
used to characterize the construction of the biosensor. The optimum values for the 
relevant experimental variables were determined.  
Using the proposed immunosensor, Aβ42 can be specifically detected within a 
range of 0.451–9028 ng/mL with a 264 pg/mL detection limit. The immunosensor 
enables real-time, rapid and highly sensitive detection of Aβ with low-cost and opens up 
the possibilities for diagnostic ex vivo applications and research-based in vivo studies. 
 
Keywords: Alzheimer’s disease, amyloid beta, electrochemical immunosensor, self-
assembled monolayers, gold nanoparticles. 
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1. Introduction 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly  
[1, 2]. AD is a neurodegenerative disorder that causes global, progressive and 
irreversible deterioration of many cognitive functions as memory, concentration, 
speaking capability, thought and eventually causes death. This deterioration leads to 
changes in behavior, personality and functional capacity, which hampers the daily life 
of the patient. As the population ages, AD is rapidly becoming an urgent public health 
problem. Nowadays, it affects 35 million individuals worldwide and it is projected to 
affect 115 million by 2050 [3]. In Portugal this number is estimated to be 90 000 [2]. 
Without the prevention and development of new therapies for AD, both health care and 
socioeconomic systems will not be able to support the financial needs of AD in the 
future [4].  
 Pathological hallmarks of AD include extracellular deposits of amyloid β 
peptides (Aβ) (senile plaques), intraneuronal inclusions of hyperphosphorylated tau 
protein in neurofibrillary tangles, together with downstream processes such as 
inflammation and oxidative stress, all of which contribute to loss of synaptic integrity, 
effective neural network connectivity and progressive neurodegeneration [3-5].  
Research gives support to the “amyloid cascade hypothesis”, which advocates 
that an imbalance between the production and clearance or degradation of Aβ in the 
brain is the initiating event in AD, leading to synaptic and neuronal dysfunction and 
degradation resulting, consequently, in cognitive disturbances [6]. 
The current diagnostic procedures of AD are difficult and are made in an 
advanced stage of the disease [4]. Therefore it is clinically important to find accurate 
markers for AD by new non-invasive methods that may facilitate the diagnostic process, 
identify patients at an earlier stage and monitor biochemical effects of the treatments 
[4].  
There is a continuing demand for fast and simple analytical methods for the 
determination of many clinical and biochemical parameters. The requirement for 
immunologically based biosensors is generally considered to be in the diagnostic field 
and particularly in the home diagnostic field. Immunoassays and immunosensors rely 
on the antibody-antigen interactions providing promising means of analysis due to their 
specificity and sensitivity. The high specificity is achieved mainly by the molecular 
recognition of the target analytes by the antibodies or antigens forming stable 
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immunocomplexes [7-9]. On the other hand, sensitivity depends on several factors, 
including the affinity of antibodies, the amount of immobilized immunological 
recognition elements, and the choice of transducer and signal probe [8]. The 
improvement of immunoassay and immunosensor performance mainly relies on the 
development of antibody preparation techniques, the improvement of immobilization 
and tagging methods, and the adoption of a high-performance transduction method [8]. 
Electrochemical detection overcomes problems associated with other immunoassays 
and immunosensors detection techniques, such as the short half-life of radioactive 
agents and concerns of health hazards, while limited sensitivity in the analysis of 
colored or turbid samples is achieved in immunoassays coupled with optical detection 
[10]. 
Electrochemistry is the science concerned with the physical and chemical 
properties of ionic conductors as well as with phenomena occurring at the interfaces 
between ionic conductors and electronic conductors or semiconductors, or even 
insulators (including gases and vacuum) [11, 12]. In other words, electroanalytical 
methods are a class of techniques in analytical chemistry which studies the relationship 
between electrical and chemical parameters enabling the detection of the analyte of 
interest by measuring the potential and/or current in an electrochemical cell. Such 
electroanalytical measurements have been found to have a vast range of applications, 
including biomedical analysis, quality control, and environmental monitoring. 
Electrochemical transducers for immunoassays and immunosensors are very attractive 
due to their high sensitivity, inherent simplicity and miniaturization, low cost and power 
requirements [8, 9, 13]. Furthermore, electrochemistry is an interfacial process in which 
the relevant reactions take place at the electrode-solution interface, rather than in bulk 
solution [12]. Therefore, in conjunction with developments in micro- and nano-
electrochemical sensors, electrochemistry offers an added bonus of detecting analytes in 
very small volumes [8, 10]. 
 
1.1 Main Objectives 
The aim of this research is to develop a sensitive gold label free immunosensor 
for the Alzheimer’s disease main biomarker, amyloid-beta peptide, in order to facilitate 
and enable early AD diagnosis. The immunosensor construction comprises three main 
steps:  
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1. Formation of a self-assembled monolayer on the gold surface in order to control 
the electrode interface. Several self-assembled monolayers (SAMs) were tested 
and experimental conditions were optimized in order to promote the best 
immobilization on the gold surface. 
2. Electrodeposition of gold nanoparticles on the modified SAM/gold electrode. 
Gold nanoparticles enhanced the biosensor response and allowed antibody 
immobilization. Different methods for gold nanoparticles synthesis were tested 
and compared.  
3. Immobilization of the antibody on the gold nanoparticles/SAM/gold electrode. 
Concentration of the antibody and time of incubation were optimized in order to 
promote the desired immobilization.  
The electroanalytical behavior of the developed biosensor was characterized in 
terms of calibration data. Finally, it was successfully applied to synthetic 
solutions of Aβ.  
    
1.2 Thesis structure 
This thesis is divided in 6 chapters. 
In Chapter 1, the key issues are introduced. The motivations to the work 
performed, as well as, the main objectives of the work are presented. 
In Chapter 2 the theoretical aspects concerning the main topics of this work are 
presented. The following subjects are discussed: the formation of extracellular deposits 
of Aβ and consequently development of AD, the main electrochemical technique 
principles, the characteristics of biosensors and immunoassays, properties of 
nanomaterials and their importance in the development of biosensors. In this section the 
recent studies related with this theme are also referred.   
Chapter 3 describes the reagents, equipments and methods used in the performed 
experiments. 
In Chapter 4, the results attained are presented and discussed. The topics include 
the characterization of the gold electrode, the SAMs formation, synthesis and 
electrodeposition of gold nanoparticles, antibody immobilization and finally detection 
of Aβ. 
Chapter 5 is the final chapter of the thesis in which the main conclusions and 
future perspectives for the work are referred. 
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2. State of the Art 
2.1 Alzheimer’s disease – The amyloid cascade hypothesis 
AD is a neurodegenerative pathology characterized by extracellular deposits of 
Aβ peptide (senile plaques), intracellular appearance of neurofibrillary tangles and 
neuronal loss. 
The amyloid cascade hypothesis defends that the deposition of the Aβ peptide in 
the brain parenchyma is a crucial step that ultimately leads to AD (Figure 1) [6, 14]. 
Autosomal dominant mutations that cause early onset familial AD occur in three genes: 
amyloid precursor protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2) [6, 14]. The 
first genetic mutations causing AD were discovered in the APP gene [6]. Most of the 
mutations cluster at or very near the sites within APP that are normally cleaved by 
proteases called α-, β-, and γ- secretases [6]. These mutations promote generation of Aβ 
by favoring proteolytic processing of APP by β- or γ-secretase [4, 6, 14]. Besides the 
mutations in the PS1 and PS2 genes that alter the APP metabolism through a direct 
effect on the γ-secretase, four important observations were given to support the amyloid 
cascade hypothesis. Firstly, the deposition of tau protein in neurofibrillary tangles in the 
brain occurs without deposition of amyloid [6]. The conclusion is that even the most 
severe consequences of tau alteration namely, neurofibrillary tangle formation leading 
to neurodegeneration, are not sufficient to induce the amyloid plaques [6]. This way, the 
formation of neurofibrillary tangle of tau is likely to be deposited after changes in Aβ 
metabolism and initial plaque formation, rather than before [6]. Secondly, studies 
suggest that altered APP processing occurs before tau alterations in the cascade of AD, 
a notion bolstered by the observation that Aβ toxicity is tau dependent [6]. Thirdly, 
studies where APP transgenic mice were crossed with apolipoprotein E (apoE) deficient 
mice, cerebral Aβ deposition was reduced in the offspring, providing strong evidence 
that the pathogenic role of genetic variability at the human apoE locus is very likely to 
involve Aβ metabolism [6, 14]. At last, evidence indicates that genetic variability in Aβ 
catabolism and clearance may contribute to the risk of late-onset AD [6]. These four 
findings reinforce the theory that cerebral Aβ accumulation is the primary event in AD. 
These studies have identified multiple steps potentially vulnerable to 
pharmacologic manipulation that resulted in the development of new drug candidates 
with disease-modifying potential [4]. This predicts a new type of causal mechanistic 
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treatment beyond symptomatic therapy [3, 4]. This new type of disease-modifying drugs 
is expected to be most effective if administrated very early in the disease process, before 
the neurodegenerative process is too severe [3, 4]. However, with the current 
techniques, the clinical diagnosis of AD can only be made when it is in an advanced 
stage. Thus, there is a great need for improved diagnostic tools and biomarkers appear 
as huge promise for the early identification of AD [3-5]. Biomarkers can provide a 
faster and more convenient responses to some questions and are playing increasingly 
diverse roles in drug development [3]. 
 
 
Figure 1 - The amyloid cascade hypothesis [6]. 
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2.2 Biomarkers for Alzheimer’s disease 
“A biomarker (biological marker) is defined as a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” [3]. In other words, 
the term biomarker is used to describe any neurochemical agent that is used to evaluate 
the risk or presence of disease. In this case, biomarkers may facilitate the ability to 
reliably diagnose AD in very early and perhaps even pre-clinical disease stages [4, 5]. 
They may also provide objective and reliable measures of drug safety and disease-
modifying treatment efficacy in clinical drug trials in AD. Since the neuropathological 
changes and symptoms of AD take years to be noticed, the ideal therapy would be to 
treat the neuropathology as early as possible and biomarkers of pre-clinical AD are 
likely to play a fundamental role in the development of new therapies [4, 5]. Biomarkers 
can provide new insights into the neurobiology of AD and generate new and novel 
therapeutic targets. Disease-related biomarkers can assist in patient selection, sample 
stratification, course prediction and defining disease severity [3]. Biomarkers may assist 
in decision making in early clinical development, may inform corporate decisions 
regarding go or non-go decisions and may decrease cycle time and decrease costs [3]. 
The key features of an ideal AD biomarker are that it should detect a 
fundamental feature of the neuropathology, and have a diagnostic sensitivity for AD 
exceeding 80% together with specificity above 80% for distinguishing AD from other 
dementias [4]. It should also be reliable, reproducible, non-invasive, simple to perform, 
and inexpensive [3, 4]. The steps to establish a biomarker consist of confirmation by at 
least two independent studies conducted by qualified investigators with the results 
published in peer-reviewed journals, and validation in neuropathologically confirmed 
cases [4]. Beyond these criteria it would also be important if the biomarker could follow 
natural disease progression even as the effects of disease-modifying therapies [3-5].  
Disease biomarkers may have important roles in three areas: as markers of trait, 
state, and rate [3, 15]. Trait markers represent risk factors and do not change with the 
presence of the disease [3, 15]. Trait biomarkers that are representative of an increased 
risk of AD include the apolipoprotein E 34 (APOE 34) allele [3, 16, 17], APOJ [3, 18, 
19], CR1 [3, 19], PICALM [3, 18], SORL1 [3, 20], and TOMM40 [3]. State markers 
indicate the presence of the disease process and include medial temporal atrophy (MTA) 
on magnetic resonance imaging (MRI), amyloid imaging, and cerebrospinal fluid (CSF) 
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Aβ and tau protein measures [3]. Rate biomarkers follow disease progression; 
progressive atrophy detected by MRI and hypometabolism observed on 
fluorodeoxyglucose (FDG) positron emission tomography (PET) are rate biomarkers 
that correlate with disease severity [3]. 
Biomarkers can be collected from a variety of biological compartments (e.g., 
imaging of brain [3], cerebrospinal fluid Aβ and tau levels [3, 21]) and each 
compartment provides a different perspective on the pathological processes of AD 
(Figure 2) [3]. Imaging biomarkers provide insight into the topographic distribution of 
pathologic changes. Fluid biomarkers may appear in the central nervous system (CNS) 
compartments by diffusion and are subject to metabolism and excretion; the status of 
these mechanisms will also affect the relationship of the biomarker to the brain disease 
[3]. 
 
Figure 2 - Biomarkers for each step in the amyloid cascade [3]. 
 
The levels of Aβ42 in the CSF in AD are reduced due to deposition of the 
peptide in Aβ plaques in the brain and the levels of Aβ40 remain unchanged or may be 
moderately increased. Several studies have examined plasma levels of Aβ in AD but the 
findings were contradictory [3, 4]. Some groups reported high levels of Aβ40 and Aβ42 
in plasma [4]. On the other hand other groups found no change in the Aβ plasma levels 
[4]. Tau protein levels in CSF increase during the development of AD [3]. Clusterin 
levels have been found to be increased in brain and CSF of patients with AD, and 
plasma clusterin was recently reported to be associated with brain atrophy, baseline 
disease severity, and rapid clinical progression in patients with AD [3]. In this study Aβ 
is the biomarker that will be explored. 
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2.2.1 Biological biomarkers of Aβ-related mechanism 
As reported earlier, Aβ is generated by proteolytic cleavage (enzymatic digestion 
involving β- and γ-secretase activities [22]) of the type I transmembrane spanning 
glycoprotein amyloid precursor protein (APP) (Figure 3) [4, 5, 14, 22]. APP is cleaved 
at the N-terminus after position 671 by a protease referred to as β-secretase, also known 
as beta-site APP-cleaving enzyme (BACE) [4, 5, 14, 22]. This cleavage results in the 
release of a large N-terminal derivative called β-secretase-cleaved soluble APP (β-
sAPP). At last, the 99 amino acid C-terminal fragment of APP (C99) is cleaved by the 
γ-secretase complex releasing free Aβ [4, 5, 14, 22]. 
 
Figure 3 - Proteolytic cleavages of APP [4]. 
 
Once released, the Aβ peptide can be identified in cerebrospinal fluid and 
plasma, what makes the various species of Aβ really interesting as candidates to 
biomarkers [4]. The mechanism that enables Aβ monomers to aggregate is not well 
understood but Aβ can exist as monomers, dimmers, oligomers, protofibrils, fibrils and 
fibrillar aggregates (Figure 4) [3, 4]. Furthermore, the tendency of Aβ to aggregate 
seems to be related with the peptide’s primary sequence as Aβ42 variant, which 
constitutes less than 10% of total Aβ, seems more prone to aggregate than more 
abundant Aβ40, contributing to the modification of the ratio Aβ40/Aβ42 [4].  
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Figure 4 - Model for Aβ misfolding and aggregation [4]. 
 
Three main synaptotoxic effects of Aβ have been recognized: inhibition of long-
term potentiation (LTP), removal of synaptic glutamate receptors and elimination of 
glutamate synapses (Figure 5) [22]. Glutamate synapses constitute 85-90% of the 
synapses in the mammalian cortex and their plasticity is thought to be the basis for 
learning and memory [22]. The postsynaptic membrane of the glutamate synapse is 
typically equipped with ionotropic AMPA and NMDA receptors [22]. The AMPA 
receptors are responsible for the normal, fast electrical signaling while the NMDA 
receptors, which are highly permeable for calcium, are required for the induction of 
LTP and its counterpart long-term depression (LTD) at these synapses [22]. LTP, a 
lasting increase in synaptic efficacy, typically involves an expansion of the synapse with 
more AMPA receptors, whereas the opposite is typical for LTD [22]. The inhibitory 
action of Aβ on NMDA receptor-dependent LTP has been shown in different 
experimental settings, including genetic modifications leading to overproduction of Aβ 
in human CSF and Aβ oligomers from AD brains [22]. 
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Figure 5 - Proposed model of Aβ-induced synaptotoxic effects and synapse elimination in AD [22]. 
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2.3 Electrochemistry 
Electrochemistry involves chemical phenomena associated with charge 
separation. Often this charge separation leads to charge transfer, which can occur 
homogeneously in solution, or heterogeneously on electrode surfaces [23]. Electrodes 
are linked by conducting paths both in solution (via ionic transport) and externally (via 
electric wires etc.) so that charge can be transported [23]. If the cell configuration 
permits, the products of the two electrode reactions can be separated.  
Electroanalytical techniques analyze the relationship between the measurements 
of electrical quantities, such as current, potential, or charge, and the chemical 
parameters [24]. The oxidation/reduction process involves the exchange of electrons 
from one specie to another. Electrochemical processes take place at the electrode-
solution interface [23, 25]. The electrochemical analyses usually require the use of three 
electrodes - the working electrode, reference electrode and counter electrode – and a 
contacting solution (electrolyte) containing the analyte [26]. The working electrode can 
be of various materials and geometries and gives response to the target analyte [26]. The 
electrode surface is thus a junction between an ionic conductor and an electronic 
conductor. The reference electrode has constant potential and is independent of the 
properties of the solution [26].  
Different types of electrical signal used for quantification reflect the differences 
between electroanalytical techniques [11, 23, 25, 27]. Such electroanalytical 
measurements have been found to have a vast range of applications, where it could be 
highlighted the biomedical analysis.  
The objective of controlled-potential electroanalytical experiments is to obtain a 
current response that is related to the concentration of the target analyte [25]. This 
objective is accomplished by monitoring the transfer of electron(s) during the redox 
process of the analyte:  
 
 
where O and R are the oxidized and reduced species, respectively. Electrode reactions 
are heterogeneous and take place in the interfacial region between electrode and 
solution, the region where charge distribution differs from that of the bulk phases [11, 
23, 25, 27]. 
                                                               O   ne-                                                  (1)                                                                                                
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The resulting current-potential plot, also known as voltammogram, is a display 
of current signal versus the potential signal [28]. The exact shape and magnitude of the 
voltammetric response is controlled by the processes involved in the electrode reaction. 
The resulting current from a change in oxidation state of the electroactive species is 
termed the faradaic current because it obeys Faraday’s law [23, 25]. The faradaic 
current is a direct measure of the rate of the redox reaction. The total current is a result 
of the sum of the faradaic currents for the sample and blank solutions, as well as the 
nonfaradaic charging background current [23, 25]. 
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2.3.1. Mass transfer 
Mass transfer is the movement of material from one location to another in 
solution. The rate of an electrode reaction is affected not only by the electrode itself but 
also by the transport of species to and from bulk solution [11, 23, 25]. It is important to 
consider the movement of ions in electrolyte solutions between anode and cathode as 
solvated ions move at different velocities, according to their size and charge. Diffusion 
is due to a concentration gradient, and migration to electric field effects [11, 23, 25]. 
Thus, whilst diffusion occurs for all species, migration affects only charged species 
(effectively, owing to the existence of dipoles, or induced dipoles in neutral species, a 
small electric field effect is observed) [11, 23, 25]. Forced convection considerably 
increases the transport of species. Natural convection, due to thermal gradients, also 
exists, but conditions where this movement is negligible are generally used [25]. 
In electrochemical systems, three modes of mass transport are generally 
considered (Figure 6): 
• Diffusion: the spontaneous movement under the influence of concentration gradient 
that is from region of high concentration to region of lower concentration aimed at 
minimizing concentration differences [25]. 
• Convection: transport to the electrode by a gross physical movement; such fluid flow 
occurs with stirring or flow of the solution and with rotation or vibration of the 
electrode (forced convection) or due to density gradients (natural convection) [25]. 
• Migration: movement of charged particles along an electrical field [25]. 
 
 
Figure 6 - Three methods for mass transfer in electrochemical systems [25]. 
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2.3.2 The electrical double layer 
The electrical double layer (Figure 7) is the array of charged particles and/or 
oriented dipoles that exists at every material interface. In electrochemistry, such a layer 
reflects the ionic zones formed in the solution to compensate for the excess of charge on 
the electrode. A positively charged electrode thus attracts a layer of negative ions (vice 
versa) [11, 23, 25, 27]. 
 
Figure 7 - Schematic representation of the electrical double layer. IHP-inner Helmholtz plane; OHP-outer 
Helmholtz plane [29]. 
The inner layer (closest to the electrode), known as the inner Helmholtz plane 
(IHP), contains solvent molecules and specifically adsorbed ions, which are not fully 
solvated [25]. It is defined by the locus of points for the specifically adsorbed ions. The 
next layer, the outer Helmholtz plane (OHP), reflects the imaginary plane passing 
through the center of solvated ions at their closest approach to the surface [25]. The 
solvated ions are nonspecifically adsorbed and are attracted to the surface by long-range 
coulomb forces [25]. Both Helmholtz layers represent the compact layer. Such a 
compact layer of charges is strongly held by the electrode and can survive even when 
the electrode is pulled out of the solution [23, 25]. However, the Helmholtz model does 
not take into account the thermal motion of ions, which loosens them from the compact 
layer [23, 25].  
The outer layer, referred to as the diffuse layer, is a three dimensional region of 
scattered ions, which extends from the OHP into the bulk solution. Such an ionic 
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distribution reflects the counterbalance between ordering forces of the electrical field 
and the disorder caused by a random thermal motion [23, 25]. 
 
2.3.3 Electrode materials 
The choice of an electrode material depends on a great extent on the useful 
potential range of the electrode in the particular solvent employed and the purity of the 
materials [11, 23, 25, 27]. The usable potential range is limited by one or more of the 
following factors: decomposition of the supporting electrolyte and electrode dissolution 
or formation of a layer of an insulating/semiconducting substance on its surface [23]. 
Additionally, solid electrodes can be adversely affected by poisoning through 
contact with solutions containing contaminants [11, 23, 27]. Of the many solid materials 
that can be used as working electrode the most frequently used are platinum, carbon and 
gold. One of the most important factors when working with solid materials is that the 
analysis is dependent of the surface state of the electrodes [23]. This way these 
electrodes need to go through a process of pretreatment and polishing to obtain 
reproducible results [23].  
Gold is most often used as redox electrode for studying electron transfer kinetics 
and mechanism, and determining thermodynamic parameters, due in large part to its 
inertness [23, 27]. Still, in certain electrochemical conditions gold can be highly active 
[23]. A general advantage of metal electrodes is that their high conductivity results in 
low background currents [11, 23, 27]. Their surfaces can be modified by 
electrodeposition or chemical modification. Another advantage of the use of metal 
electrodes is the ease of construction of the electrode assembly, and ease of polishing 
[11, 23, 27]. At last, gold has unique properties to provide a suitable microenvironment 
for biomolecules immobilization retaining their biological activity, and to facilitate 
electron transfer between the immobilized proteins and electrode surfaces.  
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2.3.4. Electrochemical Techniques 
2.3.4.1 Cyclic voltammetry 
Cyclic voltammetry (CV) is the most used technique to obtain qualitative 
information about electrochemical reactions and it is often the first applied technique for 
the electrochemical study of a compound, a biological material, or an electrode surface 
[23-26]. The application of CV results from its capability for rapidly detect the redox 
behavior over a wide potential range and to provide information on kinetics of 
heterogeneous electron-transfer reaction and on coupled chemical reactions or 
adsorption processes [23-26]. It enables the electrode potential to be rapidly scanned in 
search of redox couples. Once located, a couple can be characterized from the potentials 
of peaks on the cyclic voltammogram and from changes caused by variation of the scan 
rate [23-25]. 
 CV consists of cycling the potential of an electrode and measuring the resulting 
current [23, 25, 28]. The excitation signal for CV is a linear potential scan with a 
triangular waveform (Figure 8) [28, 30]. The potential excitation signal sweeps the 
potential of the electrode between two values, designed the switching potentials [28]. 
The excitation signal causes, in the first place, the potential to scan positively versus the 
reference electrode at which point the scan direction is reversed causing a negative scan 
back to the original value (Figure 8) [28]. 
The peak current for a reversible couple at a normal-sized planar electrode is 
described (at 298 K) by the Randles–Sevcik equation [30]: 
 
                    
                                                                                       (2) 
 
where the peak current ip is in amperes, n is the number of electrons transferred in redox 
events, the electrode area A is in cm
2
, the diffusion coefficient D is in cm
2
/s, v is in V/s
 
and the bulk concentration of the reactant c is in mol/cm
3
.  
 17 
 
 
Figure 8 - Typical excitation signal for CV - a triangular potential waveform with switching potentials at 
V1 and V2 [31]. 
 
2.3.4.2 Square-wave voltammetry 
Square-wave voltammetry (SWV) is a further improvement of staircase 
voltammetry, which is itself a derivative of linear sweep voltammetry [23, 25, 26, 32]. 
In linear sweep voltammetry the current at a working electrode is measured while the 
potential between the working electrode and a reference electrode is swept linearly in 
time. SWV is a large amplitude differential technique in which a waveform is composed 
by symmetrical square waves [23, 25, 26]. The excitation signal in SWV (Figure 9) 
consists of a symmetrical square-wave pulse of amplitude superimposed on a staircase 
waveform, where the forward pulse of the square wave coincides with the staircase step 
[23, 25, 26]. The current is sampled twice during each square-wave cycle, once at the 
end of the forward pulse and once at the end of the reverse pulse. The current is 
measured at the end of each potential change so that the contribution to the current 
signal from the capacitive charging current is minimized [25, 32]. The net current is 
obtained by taking the difference between the forward and reverse currents and is 
centered on the redox potential [25]. The peak height is directly proportional to the 
concentration of the electroactive species and direct detection limits as low as 10
–8
 
mol/L are possible [23, 25]. The fact that net current is large compared to either forward 
or backward current and coupled with effective discrimination against the charging 
current, allows the achievement of excellent sensitivity in SWV [24, 25].  
SWV has several advantages, namely excellent sensitivity and the minimization 
of background currents [23-26]. One of the major advantages is also its speed [24]. The 
effective scan rate is of the order of 500 mV/s and as a result, the analysis time is 
drastically reduced [24]. Frequencies of 1 to 100 square-wave cycles per second permit 
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the use of extremely fast potential scan rates [24]. The analysis time is reduced and a 
complete voltammogram can be recorded within a few seconds [24]. Another advantage 
of this technique is the minimization of oxygen interference. In stripping voltammetry 
during the preconcentration step the dissolved oxygen is irreversibility reduced at 
potentials sufficiently negatives and it is depleted from the electrode surface. During the 
stripping step at elevated scan rates and high frequencies, oxygen does not have enough 
time to reach again the electrode surface. The detection limits of this technique can be 
compared to those of chromatographic and spectroscopy techniques [23, 25, 32]. 
SWV is the most used voltammetric technique for quantification and it is applied 
in the study of electrode kinetics with regard to preceding, following, or catalytic 
homogeneous chemical reactions, determination of some species at trace levels, and it is 
used with electrochemical detection in HPLC [23, 25, 33]. 
 
 
Figure 9 - Schematic waveform for square-wave voltammetry [31]. 
 
 
 
 
 
 
 
 
 
 19 
 
2.3.4.3 Electrochemical Impedance Spectroscopy 
Electrochemical Impedance Spectroscopy (EIS) or AC impedance methods have 
seen tremendous increase in popularity in recent years [34]. Initially applied to the 
determination of the double layer capacitance, they are now applied to the 
characterization of electrode processes and complex interfaces [34]. EIS studies the 
system response to the application of a periodic small amplitude AC signal. These 
measurements are carried out at different AC frequencies and analysis of the system 
response contains information about the interface, its structure and reactions taking 
place there [34]. By varying the excitation frequency of the applied potential over a 
range of frequencies, one can calculate the complex impedance, sum of the real and 
imaginary impedance components, of the system as a function of the frequency (i.e. 
angular frequency, w) [35]. Therefore, EIS combines the analysis of both real and 
imaginary components of impedance, namely the electrical resistance and reactance [29, 
34, 35].  
EIS possesses the ability to study any intrinsic material property or specific 
processes that could influence the conductivity/resistivity or capacitivity of an 
electrochemical system. Therefore, EIS is a useful tool in the development and analysis 
of materials for biosensor transduction, such as the study of polymer degradation [35]. 
However it is a complementary technique and other methods must also be used to 
elucidate the interfacial processes [34, 35]. 
The electric equivalent circuit first proposed by Randles, shown in figure 10, is 
commonly used in EIS for interpretation of impedance spectra [29]. It includes a 
solution resistance (Rs), a double layer capacitor (Cd) and a charge transfer (Rct) or 
polarization resistance (Rp). When the charge transfer takes place at the interface, the 
mass transports of the reactant and product take on roles in determining the rate of 
electron transfer, which depends on the consumption of the oxidants and the production 
of the reductant near the electrode surface [29]. The mass transport of the reactants and 
the products provides another class of impedance, Warburg impedance (ZW), which can 
be exploited by electroanalytical chemists because it shows up in the form of a peak 
current in a voltammogram or a current plateau in a polarogram [29]. 
In addition, to be a useful model in its own right, the Randles model is the 
starting point for other more complex models [29]. The double layer capacity is parallel 
with the impedance due to the charge transfer reaction [29]. Figure 10 shows an 
example of a Nyquist plot for a Randles cell. The solution resistance can be found by 
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reading the real axis value at the high frequency intercept, which is the intercept near 
the origin of the plot [29]. The value at the right side of the real axis (low frequency 
region) is the sum of the charge transfer resistance and the solution resistance [29]. The 
intermediate-frequency component (circle) arising from the Rp and Cd is located in 
between [29]. In a simple situation, the Warburg element manifests itself in EIS spectra 
by a line with an angle of 45 degrees in the low frequency region [29]. 
 
 
Figure 10 - a) A schematic diagram of an idealized Randles electrical equivalent circuit [29]; b) Nyquist 
plot showing the high and low frequency components [34]. 
 
For electrochemical sensing, impedance techniques are useful to monitor 
changes in electrical properties arising from biorecognition events at the surfaces of 
modified electrodes. For example, changes in the conductivity  of the electrode can be 
measured as a result of protein immobilization and antibody-antigen reactions on the 
electrode surface [35].  
EIS has become a mature and well understood technique. It is now possible to 
acquire, validate and quantitatively interpret the experimental impedances. However, 
the most difficult problem in EIS is modeling of the electrode processes. There is almost 
an infinite variety of different reactions and interfaces that can be studied (corrosion, 
coating, conducting polymers, batteries and fuel cells, etc.) and the main effort is now 
applied to understand and analyze these processes [35]. 
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2.4 Biosensors 
Biosensors are, by definition, sensing devices including a biological component 
(enzyme, antibody, animal or plant cell, oligonucleotide, lipid, microorganisms, etc.) 
intimately connected to a physical transducer (electrode, optical fiber, vibrating quartz, 
etc.) (Figure 11) [35, 36]. This dual configuration permits a quantitative study of the 
interaction between the analyte and an immobilized biocomponent [36, 37]. Designed 
for the purpose, biosensors are generally highly selective due to the possibility to tailor 
the specific interaction of compounds by immobilizing biological recognition elements 
on the sensor substrate that have a specific binding affinity to the desired molecule [35-
38]. Typical recognition elements used in biosensors are: enzymes, antibodies, nucleic 
acids and cells. Ideally, biosensors should be readily implemented and allow for low 
reagent and energy consumption [35, 36, 39-42].  
 Nowadays, a lot of biosensors can be found in laboratories around the world but 
only one is known by its great ratio efficiency/cost and that is the glucose sensor. The 
major limitation, in several cases, in developing sensing devices is associated with the 
ability to miniaturize the transduction principle and the lack of cost-effective production 
method [37, 41]. Biosensors have an important role due to their inherent advantages as 
robustness, easy miniaturization, excellent detection limits, possibility of using small 
analyte volumes, and ability to be used in turbid biofluids with optically absorbing and 
fluorescing compounds [35]. 
 
 
Figure 11 - Components of typical biosensor [35]. 
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In order to construct a successful biosensor a number of conditions must be met  
[35]: 
 
1. The biocatalyst must be highly specific for the purpose of the analysis, be stable 
under normal storage conditions and show a low variation between assays. 
2. The reaction should be as independent as manageable of such physical 
parameters as stirring, pH and temperature. This will allow analysis of samples 
with minimal pre-treatment. If the reaction involves cofactors or coenzymes 
these should, preferably, also be co-immobilized with the enzyme. 
3. The response should be accurate, precise, reproducible and linear over the 
concentration range of interest. It should also be free from electrical or other 
transducer induced noise. 
4. If the biosensor is to be used for invasive monitoring in clinical situations, the 
probe must be tiny and biocompatible, having no toxic or antigenic effects. 
Furthermore, the biosensor should not be prone to inactivation or proteolysis. 
5. For rapid measurements of analytes from human samples it is desirable that the 
biosensor can provide real-time analysis. 
6. The complete biosensor should be cheap, small, portable and capable of being 
used by semi-skilled operators. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
2.5 Electrochemical immunosensors 
Immunosensors are affinity ligand-based biosensing devices that couple 
immunochemical reactions to appropriate transducers [43]. In recent decades, 
immunosensors have received rapid development and wide applications with various 
detection formats. The general working principle of the immunosensors is based on the 
fact that the specific immunochemical recognition of antibodies (antigens) immobilized 
on a transducer to antigens (antibodies) in the sample media can produce analytical 
signals dynamically varying with the concentrations of analytes of interest [43-45]. The 
merits of immunosensors are related to selectivity and affinity of the antibody-antigen 
reaction [46]. Here, the highly specific binding between the antibody and the antigen 
involves different types of interaction forces, basically hydrophobic and electrostatic 
interactions, van der Waals forces and hydrogen bonding. The antigen–antibody 
reaction is reversible and, owing to the relative weakness of the forces holding the 
antibody and antigen together, the complex formed would dissociate in dependence 
upon the reaction environment (e.g. pH and ion strength) [43]. High specificity is 
achieved by the molecular recognition of target analytes (usually the antigens) by 
antibodies (biological recognition element) to form a stable complex on the surface of 
an immunoassay system or an immunosensor [40, 43, 47-49]. On the other hand, 
sensitivity depends on several factors including the use of high affinity analyte-specific 
antibodies, their orientation after being immobilized on the immunoassay or 
immunosensor surface and the appropriate detection system for measuring the analytical 
signal [48, 49]. This recognition reaction defines the high selectivity and sensitivity of 
the transducer device [43]. The electronic part is used to amplify and digitalize the 
physicochemical output signal from the transducer devices such as electrochemical 
(potentiometric, conductometric, capacitative, impedance, amperometric), optical 
(fluorescence, luminescence, refractive index), and microgravimetric devices [43]. 
Electrochemical immunosensors have been applied to several fields of science 
including medical diagnosis [44, 45, 50], environmental analysis [51, 52] and biological 
process monitoring [53]. In the biological area, considerable efforts have been devoted 
to the development of precise, rapid, sensitive, and selective immunosensors by 
measurement of the markers or pathogenic microorganisms responsible for the diseases, 
such as proteins, enzymes, viruses, bacteria, and hormones [47, 54-57]. This technology 
gains practical usefulness from a combination of selective biochemical recognition with 
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the high sensitivity of electrochemical detection [58]. With the development of 
technology, such biosensors profit from miniaturized electrochemical instrumentation 
and are thus very advantageous for some sophisticated applications requiring 
portability, rapid measurement and use with a small volume of samples [58]. Several 
reviews confirm the attractive advantages of electrochemical biosensors [9, 10, 59-62]. 
 
2.5.1 The antibody-antigen interaction 
The fundamental basis of all immunosensors is the specificity of the molecular 
recognition of antigens by antibodies to form a stable complex. Antibodies are a family 
of glycoproteins known as immunoglobulins (Ig). There are generally five distinct 
classes of glycoproteins (IgA, IgG, IgM, IgD, and IgE) with IgG being the most 
abundant class (approximately 70%) and most often used in immunoanalytical 
techniques [48, 63]. IgG is a “Y”-shaped molecule based upon two distinct types of 
polypeptide chains (Figure 12). The molecular weight of the smaller (light) chain is 
approximately 25 kDa, while that of the larger (heavy) chain is approximately 50 kDa. 
In each IgG molecule, there are two light and two heavy chains held together by 
disulfide linkages [48, 63]. 
 Antibodies show very high specificity and binding constants toward their 
corresponding antigens. An antigen has been defined as any agent that gives rise to 
antibody formation specific for that agent when transferred to a living cell system 
containing cells of the immunologically competent type [48, 63]. 
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Figure 12 - A schematic illustrating the “Y”-shaped structure of an antibody [48]. 
 
2.5.2 Immunoassays 
Immunoassay is the predominant analytical technique for quantitative 
measurements, being used over a wide range of concentrations, in many different 
biological matrices, and in a range of delivery formats. Immunoassays are the 
quantitative methods of analysis where antibodies are the primary binding agents for the 
antigen (which is often the analyte) of interest [9, 43, 46, 48]. 
All immunoassays depend on measuring the fractional occupancy of the 
recognition sites. Usually, immunoassays are heterogeneous, which means that either 
the antibody or the antigen is immobilized on a solid carrier and an immunocomplex is 
formed upon contact with a solution containing the other immunoagent while 
homogeneous immunoassays take place in the solution phase. Compared to 
homogeneous immunoassays, the heterogeneous immunoassays are easily designed and 
constructed. The unbound proteins are removed by washing and the response obtained 
from the labels is proportional to the amount of protein bound. However, such a 
measurement can rely on either the evaluation of occupied sites or, indirectly, on 
measuring unoccupied sites. This leads to the development of either a “competitive” or 
a “non-competitive” immunoassay format [46, 48]. 
 In a competitive immunoassay (Figure 13), unlabeled analyte in the test sample 
is measured by its ability to compete with the labeled antigen for a limited number of 
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antibody-binding sites [46, 48]. In electrochemical immunoassays, an enzyme label or 
an electroactive label is commonly used. Quantitative analysis can be achieved by 
determining the amount of labeled analyte that interacted at the binding sites [48]. 
Therefore, with a fixed number of antibody sites, a smaller signal is expected when the 
ratio between the quantities of sample to labeled analyte is large [48]. In contrast, a 
larger signal is obtained when there is a small quantity ratio. Therefore, the signal 
produced by the bound labeled analyte is usually inversely proportional to the amount 
of sample analyte [46, 48]. 
Non-competitive immunoassays (also known as a “sandwich” immunoassay) 
give the highest level of sensitivity and specificity because of the use of a couple of 
match antibodies. In this format the sample analyte is captured by an excess of a capture 
antibody, separating it from the bulk sample [48]. The captured analyte is then exposed 
to an excess of second signal antibody (secondary antibody (Ab2)), which will only bind 
to the existing capture antibody-analyte complex [48]. This structure is a classic two-
site immunoassay complex in which the analyte is sandwiched between two antibodies 
(Figure 13). High-affinity antibodies and appropriate labels are usually employed for 
the amplification of electrochemical signal [46, 48]. Enzyme-labeled antibodies are 
often used as detection antibodies that result in amplification of the measurement signal 
[46, 48]. In an ideal non-competitive immunoassay, no signal would be produced in the 
absence of any analyte because there are no appropriate sites available for binding to the 
signal antibody [48]. However, in practice, this is not the case due to nonspecific 
interactions between the signal antibody and other components of the immunoassay 
[48]. Therefore, it is always desirable to use a blocking reagent to reduce these 
nonspecific interactions. Nonspecific adsorption also needs to be considered when 
determining the quantity of signal antibody for use in a system [48]. Although this 
immunoassay format often offers superior specificity, it can only be used for the 
quantification of analytes with two antigenic determinants that can be simultaneously 
recognized [46, 48]. Several studies using both competitive and non-competitive 
immunoassays have been reported [64-67]. 
Electrochemical detection of immunointeraction can be performed both with and 
without labeling. A frequently used format in electrochemical immunosensing is an 
amperometric immunosensor, where proteins are labeled with enzymes producing an 
electroactive product from an added substrate [9]. 
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Direct detection without labeling can be performed by cyclic voltammetry, 
chronoamperometry, impedimetry, and by measuring the current during potential pulses 
(pulsed amperometric detection). These methods are able to detect a change in 
capacitance and/or resistance of the electrode induced by binding of protein. These 
immunosensors have been developed using various substrates [9]. 
 
 
 
Figure 13 - Schematic representation of (a) competitive and (b) non-competitive immunoassay formats 
[48]. 
A critical issue in immunoassays is minimization of nonspecific binding (NSB) 
of interfering species in samples such as serum or blood, as well as NSB of the labeled 
Ab2 that arises when this signal producing species is bound to non-antigen sites on the 
sensor [68]. In labeled assays, non-enzyme Ab2 bound to sites other than the analyte 
protein still gives a signal, but it is not proportional to the analyte protein concentration. 
This can increase detection limits and degrade sensitivity [68]. NSB is usually 
minimized by washing with a cocktail that includes casein or bovine serum albumin and 
detergents in NSB blocking steps. Another solution consists in tailoring the sensor 
surface with appropriate chemical groups that can also inhibit protein adsorption, and 
one of the most effective surfaces features polyethylene glycol (PEG) moieties [69, 70]. 
Such functionalized surfaces, although useful, may still permit small amounts of NSB 
that could significantly increase background in the pg to ng/mL analyte concentration 
ranges [68]. 
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2.5.3 Antibody immobilization techniques 
Since immunosensors usually measure the signals resulting from the specific 
immunoreactions between the antigens and the antibodies, it is clear that the 
immobilization procedures of the antibodies on the surfaces of transducers should play 
an important role in the construction of immunosensors. 
The manner in which a capture antibody is immobilized on a solid phase is a 
critical aspect that requires careful consideration in the design of an immunoassay 
system, whether it is competitive or non-competitive. A desirable feature of the chosen 
method is that it results in an immobilized capture antibody that is oriented with 
minimal steric hindrance to interact favorably with its target antigen. Equally important, 
it is highly desirable to immobilize the antibody without a significant change in its 
ability to bind its antigen. Clearly, all these features have a direct bearing on the level of 
sensitivity and dynamic range achievable by an immunosystem. There are several 
strategies for immobilizing a capture antibody on a solid phase including covalent 
attachment, physical adsorption or electrostatic/physical entrapment in a polymer 
matrix. These commonly used immobilization strategies are described below [48]. 
2.5.3.1 Biotin-(strept)avidin interaction 
Specific affinity interactions for antibody immobilization have been widely used 
in immunoassay systems in recent years. The (strept)avidin–biotin interaction is one 
such example. This technique may be used to immobilize various types of biomolecules 
such as nucleic acids, polysaccharides and proteins, including the capture antibody in 
immunoassay/immunosensor systems. The technique usually involves biotinylating the 
capture antibody and coating a solid phase with either avidin or streptavidin [48, 71]. 
The avidin-biotin and biotin–streptavidin interactions are the strongest known 
non-covalent interactions, presenting dissociation constants of the order of 10
-15
 mol/L, 
between a protein and ligand [72]. The complexes formations are very rapid, and once 
formed withstand high temperatures, pH variations, and are resistant to dissociation 
when exposed to chemicals such as detergents and denaturing agents [48, 73]. Equally 
important, the use of this immobilization technique maintains the biological function of 
the immobilized antibody. In some cases, neutravidin, which is an almost neutrally 
charged variation of avidin, is used to minimize any non-specific binding by charged 
species to maintain high binding affinity for biotin [48, 71]. 
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Despite the several mentioned advantages the biotin-(strept)avidin complex is 
not amenable to multiplex experiments. Because any biotinylated molecule will bind to 
any biotin-binding protein, these reagents must be used in combination with other 
detection-probe systems (i.e., primary-secondary antibodies) for multiplex experiments. 
Also, because biotin is a biological molecule, endogenous biotin can cause background 
and specificity issues when performing assays with certain biotin-rich tissues and 
extracts (i.e., brain, liver, milk, eggs, corn). In addition, the strength of the interaction 
between biotin and avidin may also influence the application for which this binding is 
required, as the harsh conditions required to break the avidin-biotin bonds may denature 
target proteins. 
2.5.3.2 Antibody-binding proteins 
Another commonly used affinity-based immobilization technique for capture 
antibodies in immunoassay systems involves a bacterial antibody-binding protein. 
Protein A and Protein G are the two most common [48]. These proteins bind 
specifically to antibodies through their non-antigenic (Fc) regions, which allow the 
antigen binding sites of the immobilized antibody to be oriented away from the solid 
phase and be available to bind the target analyte. As these proteins interact directly with 
the Fc region of antibodies, there is no need for antibody biotinylation [48].  
Protein A has a molecular weight of approximately 42 kDa and was originally 
isolated from the cell wall of Staphylococcus aureus [74]. It is known to contain five Fc 
binding domains located towards its -NH2 terminal [48]. Optimal binding occurs at pH 
8.2, although binding is also effective at neutral or physiological conditions (pH 7.0 to 
7.6). However, the interaction between Protein A and IgG is not equivalent for all 
species. Even within a species, Protein A interacts with some subclasses of IgG and not 
others [48]. The binding capacity of Protein A is limited to three human IgG subclasses 
(IgG 1, 2 and 4) [75]. Also, Protein A will not bind to goat and rat IgG, and only weakly 
to mouse IgG [76]. 
The second bacterial antibody binding protein, Protein G, is a cell surface 
protein of group C and G streptococcus with three Fc binding domains located near its 
C-terminal, and has specificity for subclasses of antibodies from many species [75]. 
Optimal binding occurs at pH 5.0, although binding is also effective at pH 7.0 to 7.2. 
Protein G has greater affinity than Protein A for most mammalian IgGs. However there 
are inconsistencies in reported binding properties of IgG to Protein G. Variations in 
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isolation and manufacturing methods for Protein G may affect IgG binding, partially 
because there are differing numbers of IgG-binding sites on various sources of Protein 
G [48]. 
Differences in binding characteristics between Protein A and Protein G may be 
explained by the different compositions in the IgG-binding sites of each protein. The 
tertiary structures of these proteins are very similar although their amino acid 
compositions are significantly different [48]. 
2.5.3.3 Conducting polymers 
Conducting polymers such as polyaniline, polypyrrole, and polythiophene are 
commonly applied for immobilizing capture antibodies in immunoassay systems [48, 
77]. The polymers can be used in amperometric, potentiometric and impedimetric 
immunoassay systems [48, 77, 78]. Conducting polymers may provide a direct route of 
electron transfer between an enzyme and the electrode surface and, where required, 
negate the need for a mediator to shuttle electrons between the enzyme and the 
electrode [48]. Conducting polymers may also facilitate “reagentless” or “label-free” 
immunosensing [48]. A common way to immobilize antibodies involving conducting 
polymers is entrapment within the polymeric chains [77]. The antibody is usually co-
immobilized with the polymer onto the sensor surface from a monomer solution 
containing the antibody [48]. However, entrapment may result in denaturation of the 
antibody, leading to a loss of activity [48]. Furthermore, a large proportion of the 
immobilized antibody will be trapped within the polymer matrix and is thus 
inaccessible for binding to its antigen [48]. An alternative to entrapment is covalent 
attachment of the antibody to active groups on a pre-immobilized conducting polymer 
film [48, 77]. 
2.5.3.4 Antibody fragments 
Sometimes it is useful to study or make use of the activity of one portion of an 
immunoglobulin without interference from other portions of the molecule. It is possible 
to selectively cleave the immunoglobulin molecule into fragments that have discrete 
characteristics. Fragmentation of an antibody is usually achieved enzymatically with 
proteolytic enzymes such as chymotrypsin, trypsin, and papain that digest or cleave 
certain portions of the immunoglobulin protein structure [48, 79].   
The two groups of antibody fragments of primary interest are (a) antigen-binding 
fragments such as F(ab’)2 and (b) class-defining fragments such as Fc that do not bind 
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antigen [80]. Several types of antigen-binding fragments are possible, but each contains 
at least the variable regions of both heavy and light immunoglobulin chains (VH and VL, 
respectively) held together (usually by disulfide bonds) so as to preserve the antibody-
binding site [80]. Fc fragments consist of the heavy chain constant region (Fc region) of 
an immunoglobulin and mediate cellular effector functions [80]. 
Following enzymatic digestion, the disulfide linkages holding the two chains of 
the resulting F(ab’)2 fragment together are typically reduced with reagents such as 
dithiothreitol or 2-mercaptoethalamine [48]. This results in two Fab’ fragments, each 
with a terminal thiol group. The fragments thus have a high affinity for a gold surface, 
on which they can therefore self-assemble without the need of any additional reagent 
[48]. The resulting layers have an ordered arrangement with the antibody-binding 
regions being oriented in such a way that they are more accessible to bind antigen [48]. 
2.5.3.5 Self-assembled monolayers  
Many physical and chemical methods for immobilizing proteins and enzymes on 
solid surfaces, like adsorption and entrapment within membranes, are used. However, 
these techniques present some problems such as conformational change affecting the 
functional activity, adsorption with random orientation, detachment of the protein and 
fragility of the membrane resulting in less sensitivity and short longevity [43, 81]. Thus, 
there is an ever increasing demand for assembly techniques for immobilizing protein on 
the electrode surface. The well-characterized self-assembled monolayers (SAMs) on 
metal electrodes have been widely used as a new strategy for the immobilization, 
orientation and molecular organization of biomolecules at interfaces [81]. The term 
‘‘self-assembly’’ refers to the spontaneous arrangement of discrete nanometre-sized 
units from simpler subunits or building blocks into an ordered or even aggregate of 
functional entities towards an energetically stable form [82, 83]. During the self-
assembly process, the constituent subunits (atoms, molecules, biomolecules, simple 
biological structures, etc), combine in such a way that they form a secondary, more 
complex structure with fewer degrees of freedom [82]. In other words, SAMs are 
organic assemblies formed by the adsorption of molecules (or atoms) on solid surfaces 
in which intermolecular forces play a key role and which can be spontaneously formed 
from solution or from vapor phase [82, 84, 85].  
The stability of the bond between the specific functional group of a reagent and 
the electrode surface over a wide range of applied potentials and the well-defined 
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microenvironment mimicking biological membranes make such a system suitable for 
orienting proteins without denaturation and facilitating the electron transfer of proteins 
[86]. In addition, the strong inter-chain interactions (van der Waals interactions) ensure 
tight packing and stability of monolayers leading to several applications including 
chemical sensing [87], control of surface properties such as wettability and friction [84, 
88], corrosion protection [89, 90], stabilization and functionalization of nanosized 
objects (nanoparticles, nanorods, nanowires) [84, 91, 92], patterning [93] and 
semiconductor passivation [94]. 
Each of the molecules that constitute the building blocks of the system can be 
divided into three different parts (Figure 14): the headgroup (linking group), the 
backbone (main chain), and the specific terminal (active) group [82, 84]. The headgroup 
guides the self-assembly process on each type of substrate, linking the hydrocarbon 
chain (of variable length) to the metal surface through a strong bond; in many cases, the 
headgroup also has a high affinity for the surface and displaces adsorbed acidental 
organic materials from the surface [82]. The interactions among backbone hydrocarbon 
chains (involving van der Waals and hydrophobic forces) ensure an efficient packing of 
the monolayer and contribute to stabilize the structures with increasing chain length. 
This section of the molecule can also act as a physical barrier and alters electronic 
conductivity and local optical properties [82, 84]. The terminal group determines 
specific surface properties (hydrophilic, hydrophobic), and can also be used to anchor 
different molecules, biomolecules, or nanostructures by weak interactions or covalent 
bonds [82, 84, 85]. 
 
 
 
Figure 14 - Schematic diagram of an ideal, single-crystalline SAM of alkanethiolates supported on a gold 
surface. The anatomy of the SAM is highlighted [84]. 
Formation of SAM is essentially an organization of molecules that arrange 
themselves spontaneously on solid or liquid surfaces into crystalline (or semicrystalline) 
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structures, offering one of the most elegant approaches towards making ultrathin 
organic films of controlled thickness [84, 87, 95]. Thus, SAM represents an easy way to 
provide a convenient, flexible, and simple system to tailor the interfacial properties of 
metals, metal oxides, and semiconductors and link materials with totally different 
physical and chemical properties [82, 84]. The main objective is to attain the capability 
of assembling individual molecules into highly ordered architectures for obtaining a 
desired function [82, 84].  
The ease of preparation and the fact that it is possible to prepare SAMs with 
different terminal groups has converted them to the most important type of organic 
monolayer [82]. Also, SAMs can be formed not only on planar surfaces, but on objects 
of all sizes and with a variety of shapes [82]. Among SAMs, the most important and 
most extensively studied, because of their promising and current applications in several 
fields of nanotechnology are derived from the adsorption of alkanethiols on noble and 
coinage metals [84]. In addition, SAMs of arenethiols, alkanedithiols, arenedithiols are 
also studied but to a lesser extent [84]. Other SAMs on metals include those of 
dialkyldisulfides, and dialkylsulfides [84]. 
 
 
Figure 15 - Examples of sulfur compounds that form self-assembled monolayers on metals and 
semiconductors: (a) alkanethiol; (b) arenethiol; (c) alkanedithiol; (d) dialkyldisulfide; (e) dialkylsulfide. 
Red: sulfur atom, blue: carbon atom, white: hydrogen atom [82]. 
Thiol and dithiol SAMs on metals, and particularly on gold, have attracted 
considerable attention due to their easy preparation from gas phase or from solution, 
and their relatively high stability mediated by the strength of the S–Au bond and by van 
der Waals interactions [82]. These monolayers exhibit molecular order, and are 
relatively stable in ambient conditions. The high affinity of thiols for the surfaces of 
noble and coinage metals makes it possible to generate well-defined organic surfaces 
with useful and highly alterable chemical functionalities displayed at the exposed 
interface [82, 84].  
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A thiol molecule consists of three parts (Figure 16): (1) the sulfur headgroup, 
which forms a strong, covalent bond with the substrate, (2) the hydrocarbon chain (of 
variable length), which stabilizes the SAM through van der Waals interactions, and (3) 
the terminal group, which can have different functionalities [82]. A small change in the 
endgroup can be enough to change the physical and chemical properties of the layer [82, 
84, 96]. Thus, –CH3 and –CF3 groups turn the SAM surface hydrophobic, 
metallophobic [82, 89] and highly anti-adherent, while –COOH, –NH2 or –OH groups 
yield hydrophilic surfaces with good metal ion and protein binding properties [82, 97]. 
On the other hand, dithiols can be regarded as –SH-terminated thiols, and are very 
important to bind metallic ions and nanoparticles to the SAMs [84]. 
 
Figure 16 - Scheme of a decanethiol molecule adsorbed on gold. Red: sulfur atom; blue: carbon atom; 
white: hydrogen atom [82]. 
Self assembly of thiols and dithiols on gold is, in principle, easy to perform and 
can be done both in gas and liquid phase, the latter being the most popular method 
because of its simplicity and accessibility in most laboratories [82]. There are, however, 
a number of experimental factors that can affect the structure of the resulting SAM and 
the rate of formation: solvent, temperature, concentration of adsorbate, immersion time, 
purity of the adsorbate, concentration of oxygen in solution, cleanliness of the substrate, 
and chain length [84, 87]. This way and as a result of numerous studies it was 
concluded that, in general, adsorption is performed in ~1–10 mM solutions of thiols, 
dithiols, dialkyldisulfides and dialkylsulfides in different solvents, depending on the 
nature of the molecule [84]. Adsorption time also depends on the nature of the 
molecule: while 2–12 h are enough to form a well-ordered SAM in the case of long 
 35 
 
chain alkanethiols, at least 24 h are necessary for short chain alkanethiols or thiols with 
certain endgroups different from –CH3 [82]. 
 
Figure 17 - The formation process of self-assembled monolayers. 
The assembly process (Figure 17) starts with a physisorption step, followed by 
chemisorption of the molecules, and finally the formation of crystalline, ordered 
domains with molecules in a closed-packed configuration [82, 84, 85]. 
 
2.5.4 Nanomaterials based immunosensors 
The unique properties of nanoscale materials and the ability to tailor their size 
and structure offer excellent prospects for designing highly sensitive and selective 
bioassays of nucleic acids and proteins, and render them applicable in the fields of 
medical imaging and therapy [8, 98]. Nanostructured materials are interesting tools with 
specific physical and chemical properties due to quantum-size effects and large surface 
areas, which provide them unique and different properties compared to bulk materials. 
Currently, the most intense research involves applying nanomaterials in immobilization 
[99]. Nanostructured sensor surfaces allow the improvement of biosensors properties 
and additional increases in their sensitivity by providing high surface areas enabling 
attachment of a large number of capture antibodies and by facilitating better access of 
protein analytes to these antibodies, enhancing the performance of bioassays [8, 68, 98, 
100-102]. 
Nanotechnology has generated new innovative materials such as nanoparticles 
[103, 104], quantum dots [105, 106], nanowires [107, 108] and nanotubes [109, 110], 
all having unique properties applicable in delivering enhanced loading of biological 
elements, their increased stability or specificity, and enabling the use of novel 
transduction schemes. Several studies have reported about the enhancement of 
electronic properties when metallic nanostructures are used as components for 
electrodes modification [68, 101, 102].  
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Nanoparticles of different compositions and dimensions have been widely used 
in recent years as versatile and sensitive tracers for the electronic, optical, 
electrochemical and microgravimetric transduction of different biomolecular 
recognition events. The enormous signal enhancement associated with using 
nanoparticle amplifying labels and with forming nanoparticle-biomolecule assemblies 
provides the basis for ultrasensitive detection [68, 98, 101, 102, 111, 112]. Typically, 
metallic nanoparticles are prepared by chemical reduction of the corresponding 
transition metal salts in the presence of a stabilizer (often citrate, phosphanes or thiols) 
which binds to their surface to impart high stability and rich linking chemistry and 
provide the desired charge and solubility properties [98]. In the case of labile anionic 
ligands capping layers such as citrate or lipoic acid, the biomolecules are often coupled 
through noncovalent electrostatic interactions [101]. Nanoparticle labels in 
immunoassays were first reported by Dequaire et al. [113]. Metals in the nanoparticles 
served as labels after dissolution of the particles. After the antibodies capture of analyte 
proteins, Ab2-nanoparticles were added to bind to them, and a NSB blocking wash was 
done. Then, the nanoparticles were dissolved in acid to produce high concentrations of 
electroactive metal ions. With gold nanoparticle-Ab2 labels, Au
3+
 released by acid 
dissolution was detected by anodic stripping voltammetry to give a 3 pmol/L detection 
limit for IgG in buffer. Gold nanoparticles (AuNPs) have received great attention due to 
their attractive electronic, optical, and thermal as well as catalytic properties and 
potential applications in the fields of physics, chemistry, biology, medicine, and 
material science [114-119]. Therefore the synthesis and characterization of AuNPs have 
attracted considerable attention from a fundamental and practical point of view. 
The preparation of AuNPs generally involves the chemical reduction of gold salt 
in the aqueous, organic phase or in two phases [114]. However, the high surface energy 
of AuNPs makes them extremely reactive, and most systems undergo aggregation 
without protection or passivation of their surfaces [91, 114]. This way, special 
precautions have to be considered to avoid their aggregation and precipitation [114]. 
Typically the AuNPs synthesis is performed in the presence of a stabilizer which binds 
to their surface to impart high stability and high rich linking chemistry and provide the 
desired charge and solubility properties [91, 114].  
The synthesis of AuNPs was reported firstly by Faraday in 1857 [117]. To date a 
large number of methods has already been developed to synthesize AuNPs. Among 
them, there are two classic ways which are widely employed. The first method for the 
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preparation of AuNPs in aqueous solution was introduced by Turkevich [120], which 
was subsequently improved by Frens [121]. In this method, AuNPs are prepared by 
reducing tetrachloroauric acid (HAuCl4) with sodium citrate in boiling water 
(Turkevich-Frens method) [122]. The size of the synthesized AuNPs can range from 10-
100 nm by changing the gold to citrate ratio [117]. The water soluble and negatively 
charged nanoparticles obtained via this method are usually utilized in the assembly of 
nano-composites and nano-interfaces based on electrostatic interactions [117, 118]. The 
second method was developed by Brust et al. in 1994 [123]. AuCl4
-
 was reduced by 
sodium borohydride in the presence of alkane thiols in a two phase system [118]. In 
addition to spherical nanoparticles, other Au structures can be generated in various 
shapes such as nanorods [124], nanoshells [125], nanocages [126] and nanocubes [127].   
Compared to other nanomaterials, AuNPs are chemically stable, non-toxic and 
easy to functionalize. The stabilization and functionalization of AuNPs with 
biomolecular recognition motif have provided flexibility for a variety of applications, 
including bioassay, bioimaging and biosensor [115, 117, 118, 128]. As a result, DNA 
[129], enzymes [130], antibodies [131] and some functional polymers [132] can be 
easily conjugated with AuNPs without affecting their activities [118]. Different types of 
functionalized AuNPs can be developed as required [118].  
From an electroanalytical point of view, AuNPs are particularly interesting 
because of their high stability, good biological compatibility, excellent conducting 
capability, and high surface-to-volume ratio [114, 119]. These features provide 
excellent prospects for interfacing biological recognition events with electronic signal 
transduction and make AuNPs extremely suitable for developing novel and improved 
electrochemical sensing and biosensing systems [91, 114, 117, 119]. They can be 
functionalized to detect specific targets, enabling the achievement of low detection 
limits, thus offering higher sensitivity and selectivity than conventional strategies. In 
addition, AuNPs present high conductivity essential for sensors based on electrical 
detection systems [91, 115, 116, 118, 119, 128].   
Kang et al. [133] developed a sensitive immunosensor for Aβ42 using an 
electrical detection system based on scanning tunneling microscopy (STM). The 
immunosensor consisted on a sandwich immunoassay using an AuNPs-antibody 
conjugate. In this investigation, the authors concluded that β-amyloid could be 
successfully detected with electrical detection technique, achieving a 10 fg/mL 
detection limit. Georganopoulo et al. [134] used the bio-barcode system to detect 
 38 
 
protein levels with attomolar sensitivity. The method involves the capture of the analyte 
with a magnetic particle featuring recognition elements, followed by binding of 
functionalized AuNPs with a second recognition agent and “barcode” (marker) DNA 
strands. After magnetic separation of the sandwich complex, the DNA barcodes are 
released and the DNA strands detected and quantified using the Au-nanoprobe 
sandwich assay followed by silver enhancement. This method was successfully used for 
measuring the concentration of amyloid-β-derived diffusible ligands, a potential 
Alzheimer’s disease marker present at extremely low concentrations (<1 pmol/L) in the 
cerebrospinal fluid of affected individuals [134]. 
Another relevant example includes the development of a novel enhancement for 
immunochromatographic test strips where both the primary and the secondary 
antibodies are conjugated with AuNPs [135]. This experimental set-up increased the 
detection limit of the chorionic gonadotropin hormone by an order of magnitude to 
reach 1 pg/mL.  
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3. Materials and Methods 
3.1 Reagents and equipments 
Alumina solution (γ-Al2O3) 0.3 µm and 0.05 µm were purchased from 
Gravimeta. All other reagents used were of analytical reagent grade. Sulfuric acid 
(H2SO4, 98%), hydrogen peroxide (H2O2, 30% Sigma-Aldrich, Steinheim, Germany) 
and absolute ethanol were purchased from Panreac (Spain). Potassium nitrate (KNO3) 
was purchased from Pronalab (Mexico). Potassium ferrocyanide (K4[Fe(CN)6].3H2O), 
potassium ferricyanide (K3Fe(CN)6), potassium hydrogen phosphate (K2HPO4) and 
potassium dihydrogen phosphate (KH2PO4) were purchased from Riedel-de Haën 
(Germany). N-(3, Dimethylaminopropyl)-N-ethyl-carbodiimide hydrochloride (EDC), 
2-mercaptoethanol, 3-mercaptopropionic acid and glutaraldehyde solution were 
purchased from Fluka (Switzerland). N-hydroxysuccinimide (NHS), cystamine 
dihydrochloride, sodium citrate dihydrate, gold(III) chloride solution, 
ethylenediaminetetraacetic acid (EDTA), 2-imninothiolane hydrochloride, citrate buffer 
solution and 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt 
(ABTS) were purchased form Sigma-Aldrich (Steinheim, Germany). Milk powder was 
obtained from Molico Nestlé. Mouse monoclonal antibody to beta amyloid (1 mg/mL) 
IgG (ab11132) was purchased from Abcam (U.K). Human antigen β-amyloid peptide 
(1-42) was purchased from Genscript (USA). Goat anti-mouse IgG secondary antibody 
was purchased from Pierce antibodies/Thermo Scientific. Ultrapure water  
(18.2 MΩcm-1 resistivity) was produced by a Milli-Q Simplicity 185 system (Millipore, 
Molsheim, France). Nitrogen (99.999%) was obtained from LINDE (Portugal).  
The supporting electrolyte for the electrochemical studies was the phosphate 
buffer solution (0.1 mol/L, pH=7.4). A solution of 10 mmol/L 
K3[Fe(CN)6]/K4[Fe(CN)6] was prepared in KNO3 (1 mol/L).  
pH measurements were performed using a pH meter (GLP 22, Crison) with a 
combined glass electrode.  
Weight measurements were performed using an analytical balance (Mettler 
Toledo) with a 0.00001 g precision.  
8 inches microcloth polishing cloth (Buehler) was used to perform the 
mechanical cleaning of the working electrode.  
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3.2 Electrochemical analyses 
All voltammetric measurements were performed using Autolab electrochemical 
system (Eco Chemie, The Netherlands) equipped with PGSTAT-30 and General 
Purpose Electrochemical system for Windows (GPES) software (Figure 18). The 
electrochemical cell was assembled using a conventional three-electrode cell which 
included the developed biosensor (based on a polycrystalline gold electrode, BASi MF-
2014, surface area 2.0 mm
2
) as a working electrode, a glassy carbon as counter-
electrode and a Ag|AgCl|KClsat reference electrode to which all potentials are referred 
(Figure 19). 
All experiments were evaluated by square-wave voltammetry (SWV) and 
electrochemical impedance spectroscopy (EIS) using Fe(CN)6
3-
/
4-
 as electroactive 
indicator. SWV measurements were performed in a 0.1 mol/L PBS solution (pH=7.4) 
containing 0.01 mol/L of K3[Fe(CN)6]/K4[Fe(CN)6] by varying the potential from 0.00 
to 0.600 V at a 0.405 V/s scan rate. The optimal SWV parameters were a frequency of 
100 Hz, amplitude of 40 mV and scan increment of 4 mV. EIS measurements were 
performed in a 0.01 mol/L K3[Fe(CN)6]/K4[Fe(CN)6] solution using a frequency range 
from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 5 mV. Before the analysis, a 5 
min nitrogen purge was performed.  
 
Figure 18 – Potentiostat PGSTAT-30 (Autolab). 
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Figure 19 – a) Electrochemical cell assembly. Red: Working electrode; Black: Counter electrode; Blue: 
Reference electrode; b) Working electrode (gold electrode). 
 
3.2.1 Pre-treatment of the working electrode 
The pre-treatment of the gold electrode includes three stages: mechanical 
cleaning, chemical oxidation and electrochemical activation of the surface. The gold 
electrode was mechanically cleaned by polishing with γ-Al2O3 (0.3 μm and 0.05 μm) 
and then rinsed with water. Next, the gold electrode was immersed in piranha solution 
(H2O2:H2SO4, 1:3, v/v). For the electrochemical activation of the surface (to create –
COOH and –OH functional groups onto the gold electrode), the electrode was cycled 
from 0.0 to +1.6 V in 0.5 mol/L H2SO4 solution at 100 mV/s. The electrochemical 
activation stage was also used to ensure the cleanliness of the gold electrode. The 
process was repeated until typical gold cyclic voltammograms were obtained.   
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3.2.2 Self-assembled monolayers 
Several self-assembled monolayers (SAM) to modify the gold electrode surface 
were tested by immersing the gold electrode in 200 µL of the different SAM solutions 
for a 12 h period at room temperature: cystamine SAM 0.02 mol/L; cystamine and 
mercaptoethanol mixed SAM (100 µL cystamine 0.02 mol/L + 100 µL mercaptoethanol 
0.02 mol/L); mercaptopropionic acid 1 mmol/L; mercaptopropionic acid and 
mercaptoethanol mixed SAM (100 µL mercaptopropionic acid 1 mmol/L + 100 µL 
mercaptoethanol 1 mmol/L). Ethanol was the utilized solvent to prepare the SAM 
solutions. 
After washing with ultrapure water, the modified electrodes with cystamine were 
immersed in a 3% glutaraldehyde solution for 30 minutes. On the other hand, the 
modified electrodes with mercaptopropionic acid were immersed in a EDC/NHS 
solution (10 mg EDC + 10 mg NHS diluted in 500 µL PBS pH=7.4) for 30 minutes. 
After selection of the appropriate SAM, the time of immersion and concentration 
of the solution for the SAM formation were optimized.  
 
3.2.3 Synthesis and electrodeposition of gold nanoparticles 
The gold nanoparticles (AuNPs) were synthesized by two different methods. In 
the first method AuNPs were synthesized in accordance with the Turkevich-Frens 
method by reduction of HAuCl4 using sodium citrate [122]. Tetrachloroauric acid 
(HAuCl4) aqueous solution (12.5 mL H2O + 8.86 µL HAuCl4) was warmed to slight 
boiling with continuously mechanical stirring. 1.25 mL of trisodium citrate 11.42 g/L 
were added and boiled for 15 min. The AuNPs solution was cooled at room temperature 
and stored at 4 ºC until further use. Hydrodynamic size and potential zeta values were 
characterized by dynamic light scattering and laser doppler velocimetry, respectively, 
using a Zetasizer Nano ZS (Malvern, UK), at 25ºC. AuNPs were also evaluated by 
UV/vis spectrophotometry (Shimadzu UV-1700 PharmaSpec spectrophotometer) at 527 
nm. AuNPs electrodeposition on SAM modified gold electrode was carried out at -0.2 V 
for 600 s. 
In the second method, the modified gold electrode was immersed in a 0.1 mol/L 
KNO3 solution containing 3 mmol/L of HAuCl4. AuNPs were synthesized during the 
electrochemical deposition by applying a -0.2 V potential for 200 s. Then the 
electrodeposition period was optimized. 
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3.2.4 Antibody immobilization 
Antibody against β-amyloid was immobilized on the AuNPs using thiol (-SH) 
groups. In order to promote immobilization with the proper orientation the antibody was 
prepared through chemical modification (thiolation) with EDTA and iminothiolane. A 
mixed solution containing 1 µL of EDTA (0.28 mol/L), 82.6 µL of iminothiolane (0.198 
mg/mL) and monoclonal antibody against Aβ42 was prepared after dilution with PBS; 
the volume of PBS added to the antibody was the necessary to make up a volume of 111 
µL. The prepared solution reacted for 45 to 50 minutes at room temperature. After 
reaction 389 µL of PBS were added to the solution in order to make up a volume of 500 
µL and the resulting solution was purified by passing it through a sephadex PD 
MiniTrap G-25 column (GE Healthcare), following the gravity protocol. In a first 
instant, the flow-through of the column was discarded. Then the column was eluted with 
1.0 mL of PBS and the eluate was collected to an eppendorf. Three concentrations of 
antibody in PBS were tested (1.0 µg/mL, 2.5 µg/mL and 5.0 µg/mL). The SAM/AuNPs 
modified gold electrodes were immersed in 300 µL of the different antibody solutions, 
reacted for 2 h at room temperature and then were incubated at 4 ºC for 12 h. After 
concentration optimization, the incubation time was also optimized. For that purpose, 
five incubation times were tested 2.5, 5, 7.5, 10 and 12.5 h.  
 
3.2.5 β-Amiloyd (1-42) detection 
 Firstly in order to evaluate the necessary time to promote the antibody-antigen 
reaction, an indirect ELISA assay was performed using ABTS as the detection product. 
The end product is green and the absorbance was measured at 405 nm. For the 
performance of the ELISA test the antigen was diluted in PBS (pH=7.4) to a final 
concentration of 90 µg/mL and the antigen was immobilized on the wells of a 96 well 
plate (Nunc MaxiSorp). The plate was then covered with an adhesive plastic and 
incubated at 37 ºC for 1 h. After the antigen immobilization it was necessary to block 
the remaining protein-binding sites in the coated wells by adding 10% non fat dry milk. 
The plate was covered with an adhesive plastic and incubated at 37 ºC for 1 h. Then 
diluted primary antibody was added to the coated wells and incubated at room 
temperature for 5 min.  Next, the conjugated secondary antibody diluted in 3% non fat 
dry milk was added to the coated wells. At last, the substrate solution (ABTS) was 
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added and after sufficient colour development the optical density was measured at 405 
nm. After each step the coated wells were washed three times with PBS. 
 After immobilization of the antibody and after washing with ultrapure water, the 
antibody/AuNPs/SAM modified gold electrodes were immersed in 300 µL of β-amyloid 
(1-42) solution for 5 min at room temperature. The antigen solutions were prepared in 
0.1 mol/L PBS solution (pH=7.4). In this study eight antigen concentrations, 9028, 
4514, 2257, 903, 451, 45.1, 4.51 and 0.451 ng/mL were used. The inhibition 
percentages (IR, %) and the selected antigen concentrations were employed to obtain 
the analytical data. The inhibition percentage (% IR) was calculated using the following 
equation (3): 
 
%IR=[1-(Ip/Ipº)] ×100                                                                                                     (3)  
where Ipº and Ip are the peak currents before and after the incubation of the biosensor in 
the presence of the antigen solution.  
The standard deviation of the intercepts and the average of slopes of the straight 
lines from the analytical curves were used to determine the detection (LOD) and 
quantification limits (LOQ) [136]. All measurements were made, at least, in duplicate. 
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4. Results and Discussion 
4.1 Characterization of the electrode surface  
The gold electrode (AuE) surface was qualitatively evaluated by cyclic 
voltammetry (Figure 20) in order to ensure that the surface was clean and appropriate to 
be modified in the subsequent experimental steps.  
 
Figure 20 - Typical cyclic voltammogram obtained with a gold electrode in 0.5 mol/L H2SO4 aqueous 
solution at a 100 mV/s scan rate. 
The characteristic voltammogram obtained (Figure 20) is in agreement with 
those found in literature [137]. In the first instants, the current is associated with 
charging of the double layer capacitance (Figure 7) [137]. Secondly, surface 
oxidation/reduction processes occur. Then in response to a change of potential with 
time, a faradaic current flows through the interface [137]. Surface processes are 
electrochemically limited by the quantity of a given material that can be deposited, 
reduced or changed at the gold interface, thereby giving rise to current peaks [137]. As 
observed in Figure 20, the voltammogram exhibited two broad oxidation peaks at 1.1 
and 1.3 V, attributed to the formation of Au surface oxides, and a sharp reduction peak 
at 0.9 V due to subsequent removal of the oxides. 
The profiles of cyclic voltammograms depend highly on the interface between 
the solution and the electrode. The state (chemical and physical) of the gold electrode is 
of vital importance in such experiments [137]. Also the electrolyte, chemicals, 
glassware, gas used to perform the purge of the solution, tubing for the gas, all have to 
be of high purity and extremely clean . 
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4.2 Biosensor construction 
4.2.1 Modification of the AuE with self-assembled monolayers  
Self-assembled monolayers (SAMs) have been used in electroanalytical 
chemistry for 30 years as the basis of electrochemical sensors [86]. SAMs are 
essentially organic assemblies that arrange themselves spontaneously at the solid-liquid 
interface induced by strong chemisorption between the substrate and the head group 
[87]. The main objective is the ability to modify and control the interface of certain 
materials by the assembling of individual molecules into highly ordered architectures, 
ensuring a homogeneous behavior of the surface, with a specific function.  
Self-assembled monolayers offer several attractive features for applications in 
biosensors. First, since they use only the bare minimum resources, miniaturization is 
easy [87]. Secondly, the high degree of organization and dense nature of the SAMs 
chains mimic the cellular microenvironment of lipid bilayer structures providing novel 
substrates for the immobilization of biomolecules or biological systems [87]. In 
addition, the ability to select the functional groups of the monolayers allows better 
control of the nanoarchitecture, enabling the attachment of nanoclusters of either metals 
or semiconductors [87]. One of the most important advantages of SAMs consists on its 
easy preparation. The substrate just has to be immersed in a dilute solution of the 
adsorbate at a selected temperature for a specific period of time. Moreover compatibility 
with metal substrates (Au, Ag, etc.) for electrochemical measurements enables special 
benefits for biosensor applications involving current or potential measurements [87]. At 
last, the chemical stability presented by these monolayers even after the coupling with 
biomolecules for biological sensing makes them suitable to work as biosensor and 
immunosensors [87]. This way, SAMs composed of thiols or dithiols on metals, 
particularly on gold, have been the focus of considerable attention due to the fact of 
combining the mentioned characteristics, especially the ease of preparation and the high 
stability attained from the S-Au bond and by van der Walls interactions [82, 86, 87].   
Several factors affect the formation and packing density of monolayers like the 
nature and roughness of substrate, solvent, nature and concentration of the adsorbate, 
and the temperature [87]. Cleanliness and crystallinity of the substrate also play a 
crucial role in determining the compactness of the SAM [87]. These facts highlight the 
importance of the pre-treatment stage and the SAM formation should be performed 
immediately after this step. The time of immersion of the substrate in the solution also 
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plays an important role in the SAM formation and usually high concentrations require 
low immersion periods. 
In this work four different SAMs to modify the gold electrode surface were 
studied and as mentioned previously the redox pair Fe(CN)6
3-
/
4-
 was used to study the 
electrochemical behaviour of the gold electrode before and after the depositions. The 
modification of the gold electrode with the SAMs led to a block in the electron transfer 
between the surface of the electrode and the solution which consequently caused a large 
signal reduction, as it can be observed in Figure 21. This fact shows that the adsorption 
of the SAMs on the gold electrode surface was successful. The SAMs that best adsorbed 
to the electrode surface were the ones that caused the largest signal reduction. From 
observation of Figure 21, it can be concluded that the SAMs composed of 
mercaptopropionic acid, cystamine and mercaptopropionic acid+mercaptoethanol 
achieved better adsorptions. On the other hand cystamine+mercaptethanol mixed SAM 
adsorbed in a lesser extend onto the gold surface as the signal reduction was not so large 
when compared to the other SAMs. 
 
Figure 21 - Comparison of the different square-wave voltammograms before (AuE) and after the 
modification with the different self-assembled monolayers (12 h immersion): cystamine SAM (CYS); 
cystamine and mercaptoethanol mixed SAM (CYS+ME); mercaptopropionic acid SAM (MPA); 
mercaptopropionic acid and mercaptoethanol mixed SAM (MPA+ME). Profiles obtained in a 0.1 mol/L 
PBS solution pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
The SAMs functional groups were properly activated. In the case of cystamine 
SAMs, the amina group (-NH2) was activated by a glutaraldehyde solution, and the 
AuE 
CYS+ME/AuE 
CYS/AuE 
MPA+ME/AuE 
MPA/AuE 
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carboxylic (-COOH) group of the mercaptopropionic acid SAMs was activated by an 
EDC/NHS solution enabling future anchoring of proteins or nanomaterials.  
At this stage the objective was to choose the most appropriate SAM to modify 
the gold electrode. That way, mercaptopropionic acid SAM was the selected one as it 
presented the largest signal reduction. 
The most common protocol for preparing SAMs on gold is immersion of the 
clean substrate into a dilute ethanolic (1~10 mmol/L) solution for ~12-18 h at room 
temperature [84]. In order to optimize the biosensor construction, shorter immersion 
times for the selected mercaptopropionic acid SAM (1 mmol/L) were tested in this 
work. From Figure 22 it can be concluded that a 2 h immersion time was enough to 
promote the formation of the mercaptopropionic acid SAM on the gold surface. 
 
 
Figure 22 – Square-wave voltammograms obtained for different immersion periods of the gold electrode 
(AuE) on the 1 mmol/L mercaptopropionic acid solution. Profiles obtained in a 0.1 mol/L PBS solution 
pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
 Applying the optimum immersion time, the concentration of the 
mercaptopropionic acid solution was also optimized. Five concentrations ranging from 
1 to 20 mmol/L were studied. As it can be observed in Figure 23, the appropriate 
concentration to promote the formation of the SAM for a 2 h period was 5 mmol/L as it 
attained the more stable, largest and reproducible signal reduction. 
AuE 
MPA 2 h 
MPA 12 h 
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Figure 23 - Square-wave voltammograms obtained for different concentrations of MPA solution for a 2 h 
immersion period. Profiles obtained in a 0.1 mol/L PBS solution pH=7.4 containing 0.01 mol/L  
Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
 Figure 24 shows the impedance spectra recorded for the gold electrode before 
and after the SAM formation. The diameter of the semicircle in the Nyquist plot, which 
indicated the electron transfer resistance of the layer, can be used to describe the 
interface properties of the electrode for each modification step. The immobilization of 
the mercaptopropionic acid SAM led to a significant change in the impedance spectra 
when compared to the bare gold electrode which showed a straight line characteristic of 
a diffusion limit process. The MPA SAM formation on the gold electrode surface 
induced an increase in diameter of the semicircle component of the Nyquist plot which 
reflects the formation of an organized and packed layer that increases the charge-
transfer resistance.  
MPA 1 mmol/L 
MPA 5 mmol/L 
 
 50 
 
 
Figure 24 - Nyquist plot of electrochemical impedance spectra for bare gold electrode (AuE) and MPA 
SAM modified gold electrode. Profiles obtained in a 0.01 mol/L Fe(CN)6
3-/4-
 solution by applying a 
frequency range from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 5 mV.  
 
4.2.2 Deposition of gold nanoparticles onto the MPA/AuE  
In recent years, the field of electrochemical biosensors design has been capable 
of providing better analytical characteristics in terms of sensitivity, selectivity 
reliability, ease of use and low cost. As a kind of novel material, nanoparticles show 
new strategies to enhance signal response and may help developing novel sensors for 
biomedical applications [119, 128]. Nanosized particles of noble metals have been the 
source of particular interest due to their distinct physical and chemical properties. The 
catalytic capacity of metal nanoparticles to amplify the electrochemical reactions gives 
them a significantly priority in the construction of electrochemical biosensors.  
AuNPs can promote the link between the redox centers in proteins and electrode 
surfaces due to their excellent conductivity and catalytic properties [138]. AuNPs are 
highly stable and less vulnerable to degradation caused by the solution matrix [138]. 
Moreover, AuNPs are non-toxic, easy to functionalize, biocompatible to both in vivo 
and in vitro environments and present a large surface area to volume ratio. That way, 
AuNPs provide a great interface for biological recognition and electronic transduction 
which make them become an essential part in bioelectrochemistry [118]. Therefore 
AuNPs are employed as substrate to immobilize proteins or enzymes to provide a 
AuE 
MPA/AuE 
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suitable microenvironment on the electrode and lend more freedom of orientation to 
enhance the direct electron transfer behavior [55].   
In this work two methods were used to synthesize the AuNPs. Firstly, the 
AuNPs were synthesized by the Turkevich-Frens method [122]. As mentioned 
previously, in this method AuNPs were prepared by reducing tetrachloroauric acid 
(HAuCl4) with sodium citrate in boiling water. Produced nanoparticles were 
spectrophotometrically characterized in a range of 200 to 700 nm (Figure 25). From 
wavelength analysis of the predominant detected peak, the AuNPs size may be 
estimated in accordance with Link et al. [139]. That way, from observation of Figure 25 
it is possible to conclude that the nanoparticles solution exhibits an absorbance peak at 
527 nm which correspond to a diameter of 30 ± 10 nm [139]. This data is in accordance 
with the AuNPs characterization performed by dynamic light scattering. From these 
measurements it was concluded that the nanoparticles presented a hydrodynamic size of 
36.8 ± 0.57 nm. The potential zeta of the AuNPs was -38.1 ± 2.1 mV, confirming the 
stability of the nanoparticles attained by the citrate-capped effect.   
 
Figure 25 - Absorption spectrum of the gold nanoparticles prepared by the Turkevich-Frens method.  
  
The immobilization of AuNPs onto the MPA/AuE is usually performed by two 
methods: electrodeposition or/and by covalent and electrostatic interactions with self-
assembled monolayers that present the appropriate functional groups for that purpose. 
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In this work the nanoparticles were immobilized on the mercaptopropionic acid SAM 
by electrodeposition, which consists in the application of -0.2 V for 600 s.  
The second method tested for the AuNPs synthesis is based on the 
electrodeposition process that occurs at -0.2 V for 200 s when the MPA/AuE is 
immersed in a KNO3 solution containing HAuCl4 [140]. The AuNPs deposition on the 
MPA/AuE led to a significantly signal enhancement of the Fe(CN)6
3-/4-
 redox pair 
(Figure 26) associated with the increase of the gold electrode area and conductivity.  
 
Figure 26 - Square-wave voltammograms obtained for the bare gold electrode (a), after modification with 
the 5 mmol/L MPA SAM (b), and electrodeposition of AuNPs synthesized by the Turkevich-Frens 
method during 600 s (c) and by the potential application during 200 s (d). Profiles obtained in a 0.1 mol/L 
PBS solution pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
 From Figure 26 it can be concluded that the AuNPs synthesized by the both 
methods caused approximately the same signal enhancement when deposition is applied 
during 600 and 200 s, respectively for the AuNPs produced by the Turkevich-Frens 
method and by electrodeposition. Consequently, this second procedure was chosen to 
obtain the AuNPs/MPA/AuE biosensor since it constitutes a simpler and faster process.       
 The results of the optimization of AuNPs electrodeposition time are presented in 
Figure 27. It can be concluded that a 100 s period is sufficient to promote a successful 
synthesis and deposition of AuNPs since the three tested period of time promoted 
almost the same signal enhancement.  
 
a) 
b) 
c) 
d) 
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Figure 27 – Square-wave voltammograms obtained with the bare gold electrode (AuE) and 
AuNPs/MPA/AuE biosensor for different AuNPs electrodeposition periods. Profiles obtained in a 0.1 
mol/L PBS solution pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
 EIS was also applied since it is an effective tool for the characterization of the 
interface properties of the electrode surface during different modification steps. The 
obtained Nyquist diagrams at the bare AuE, MPA/AuE and AuNPs/MPA/AuE sensor 
are exhibited in Figure 28.  At high frequencies, the diameter of the semicircular portion 
controls the electron transfer kinetics of the redox process at the electrode interface. It 
dramatically decreased after modification of the MPA/AuE with AuNPs. In the presence 
of AuNPs the system exhibited a better performance as electrochemical biosensor. 
AuNPs are widely used nanomaterials because of their large surface area, strong 
adsorption ability, and high conductivity [114, 115, 118]. Their conductivity 
characteristics improve the electron transfer at the electrode surface. They can strongly 
interact with biomaterials and they have been used as a mediator to immobilize 
biomolecules and to efficiently retain their activity. Thus they will enable the 
immobilization of the antibody. At lower frequencies, the linear part is typical of a mass 
diffusion-limited electron-transfer process. 
  
 
AuE 
100 s 
150 s 
200 s 
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Figure 28 - Nyquist plot of electrochemical impedance spectra for bare gold electrode (AuE), MPA/AuE 
and AuNPs/MPA/AuE. Profiles obtained in a 0.01 mol/L Fe(CN)6
3-/4-
 solution by applying a frequency 
range from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 5 mV. 
 
4.2.3 Antibody immobilization onto the AuNPs/MPA/AuE 
 The antibodies were functionalized through chemical modification (thiolation) to 
promote the antibody immobilization with the proper orientation. The objective of this 
treatment was to encourage the antibody immobilization to the AuNPs using thiol 
groups created in the Fc section of the antibody (Figure 12) in order to make the antigen 
binding site available. For this purpose the antibody was treated with Traut’s reagent, or 
2-iminothiolane, and EDTA. The reagent reacted with the amine groups in the 
antibodies to result in permanent modifications containing terminal sulfhydryl residues 
[141]. EDTA was required to stop completely metal-catalyzed oxidation of sulfhydryl 
groups [141]. Three concentrations (1.0, 2.5 and 5.0 µg/mL) of antibody were tested 
and a large signal reduction for the Fe(CN)6
3-/4-
 redox couple was observed  (Figure 29). 
This peak diminution is caused by the partial blockage of the AuNPs/MPA/AuE surface 
by the antibodies making the electron transfer process between the electrode and the 
solution slower and more difficult. The spectra attained by EIS (Figure 30) also 
supported these results confirming that the antibody was successfully immobilized at 
the AuNPs/MPA/AuE surface. The semicircle diameter at high frequencies was 
significantly enlarged after immobilization of the antibody and the enlargement of the 
semicircle diameter seemed proportional to the antibody concentration.  
AuE 
MPA/AuE 
AuNPs/ MPA/AuE 
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Figure 29 – Square-wave voltammograms obtained for AuNPs/MPA/AuE and AuNPs/MPA/AuE 
modified with different antibody concentrations for a 12 h incubation time. Profiles obtained in a 0.1 
mol/L PBS solution pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
   
Figure 30 - Nyquist plot of electrochemical impedance spectra for AuNPs/MPA/AuE and 
AuNPs/MPA/AuE modified with different antibody concentrations. Profiles obtained in a 0.01 mol/L 
Fe(CN)6
3-/4-
 solution by applying a frequency range from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 
5 mV. 
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 The concentration that seems to best suit the objective of the work was the 
amount of 1.0 µg/mL because a high or complete blockage of the surface is undesirable 
since it would difficult or preclude the antigen quantification. Despite the lower signal 
reduction achieved with the concentration 1.0 µg/mL, an optimization of the incubation 
time was performed in order to accomplish a successful immobilization of the 
antibodies that enabled at the same time the quantification of Aβ42. Five incubation 
times (2.5, 5, 7.5, 10 and 12.5 h) were tested and the results achieved are exhibited in 
Figure 31. The 7.5 h incubation time was selected as the most adequate since the signal 
was reduced to approximately half of the one obtained with AuNPs/MPA/AuE. It 
ensures the successful antibody immobilization and still enables future antigen 
quantification. The lower incubation times (2.5 and 5 h) caused a slight signal reduction 
which did not assure a good antibody immobilization. On the other hand, the highest 
incubation times (10 and 12.5 h) caused a large signal reduction which would not allow 
the antigen quantification to be performed.     
 
 
Figure 31 - Square-wave voltammograms obtained with the AuNPs/MPA/AuE and the 
AuNPs/MPA/AuE modified with different antibody (1.0 µg/mL) incubation times. Profiles obtained in a 
0.1 mol/L PBS solution pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
The impedance spectra attained with the AuNPs/MPA/AuE modified with 
different antibody (1.0 µg/mL) incubation times are presented in Figure 32. The results 
are in agreement with those obtained by square-wave voltammetry. The diameter of the 
AuNPs/MPA/AuE 
2.5 h 
5 h 
7.5 h 
10 h 
12.5 h 
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semicircles was proportional to the incubation times. In the case of higher incubation 
times it was observed an increase in the electron transfer resistance which corresponds 
to the immobilization of higher amounts of antibodies on the biosensor. On the other 
hand lower incubation times exhibited small diameters which exalts the immobilization 
of small amounts of antibodies facilitating the electron transfer process between the 
modified gold electrode and Fe(CN)6
3-/4-
. Figure 33 summarizes the results of 
impedance spectroscopy concerning the biosensor construction. 
 
Figure 32 - Nyquist plot of electrochemical impedance spectra for the AuNPs/MPA/AuE modified with 
different antibody (1.0 µg/mL) incubation times. Profiles obtained in a 0.01 mol/L Fe(CN)6
3-/4-
 solution 
by applying a frequency range from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 5 mV. 
 
 The next step after antibody immobilization usually is the immobilization of 
bovine serum albumin (BSA) in order to minimize the nonspecific binding of 
interfering species present in samples such as serum and blood [68]. However as this 
sensor was only studied in PBS solutions containing Aβ42 the risk of occurring 
nonspecific bindings was abolished. Nevertheless, it is important to refer that this is an 
important step and it is going to be implemented before future tests in samples such as 
serum, blood or cerebrospinal fluid. 
 
2.5 h 
5 h 
7.5 h 
10 h 
12.5 h 
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Figure 33 - Nyquist plot of electrochemical impedance spectra for the AuE, MPA/AuE, 
AuNPs/MPA/AuE and Anti-Aβ42/AuNPs/MPA/AuE. Profiles obtained in a 0.01 mol/L Fe(CN)6
3-/4-
 
solution by applying a frequency range from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 5 mV. 
 
4.3 Amyloid β (1-42) detection 
 In order to evaluate the necessary time to promote the antibody-antigen reaction, 
an indirect ELISA assay performed at 405 nm using ABTS as the detection product was 
performed. The final product is green making easy to detect the development of the 
reaction. As a result of this test it was concluded that a 5 min period was enough to 
promote the link between the antigen and the antibody. 
Square-wave voltammetry was used to analyze Aβ42 concentrations based on 
the current intensity Ipº and Ip measured before and after the incubation of the 
immunosensor in the presence of the antigen solution. The antibody-antigen interaction 
led to a signal reduction caused by the blockage of the surface making the electron 
transfer process between the Anti-Aβ42/AuNPs/MPA/AuE surface and Fe(CN)6
3-/4-
 
more difficult. The decrease of the peak current intensities is proportional to the 
increase of the Aβ42 concentration (0-9028 ng/mL) (Figure 34). These results of SWV 
and EIS (Figure 35) indicate that the binding of the Aβ42 antigen to the Aβ42 antibody 
further blocks the electrode transfer barrier and increases the electron transfer resistance 
in electrochemical impedance measurements. 
 
 
AuE 
MPA/AuE  
AuNPs/MPA/AuE 
Anti-Aβ42/AuNPs/MPA/AuE  
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Figure 34 - Square-wave voltammograms obtained with the Anti-Aβ42/AuNPs/MPA/AuE 
immunosensor after expositions to different Aβ42 concentrations (0 to 9028 ng/mL). Profiles obtained in 
a 0.1 mol/L PBS solution pH=7.4 containing 0.01 mol/L Fe(CN)6
3-/4-
 at a 0.405 V/s scan rate. 
 
 
Figure 35 - Nyquist plot of electrochemical impedance spectra observed with the Anti-
Aβ42/AuNPs/MPA/AuE immunosensor after expositions to different Aβ42 concentrations (0 to 9028 
ng/mL). Profiles obtained in a 0.01 mol/L Fe(CN)6
3-/4-
 solution by applying a frequency range from 10
-1
 to 
10
5
 Hz with an amplitude perturbation of 5 mV. 
 
Figure 36 shows the several stages for the biosensor construction. Figure 37 
shows the same process but in an impedance spectra reached in a solution of 0.01 mol/L 
of Fe(CN)6
3-/4-
. The diameter of the semicircle in the Nyquist plot, which exhibits the 
electron transfer resistance of the layer, can be used to describe the interface properties 
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of the electrode for each immobilized step. Firstly, the bare gold electrode exhibited a 
straight line characteristic of the diffusion limit process. Secondly, the 
mercaptopropionic acid SAM was immobilized on the gold electrode, blocking its 
surface and increasing the electron transfer resistance leading to an enlargement of the 
semicircle diameter. Then AuNPs were electrodeposited onto the MPA/AuE decreasing 
significantly the electron transfer resistance and consequently the semicircle diameter 
was reduced to an almost straight line. In the next step AuNPs/MPA/AuE was 
immersed in the antibody solution (1.0 µg/mL) for 7.5 h and the immobilized antibody 
hindered the electron transfer process increasing again the diameter of the semicircle. At 
last, the Anti-Aβ42/AuNPs/MPA/AuE was immersed for 5 minutes in an antigen 
solution causing an even higher blockage of the surface, leading to the increase of the 
electron transfer resistance and consequently an increase of the semicircle diameter. 
 
 
Figure 36 - The several steps for the biosensor construction. 
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Figure 37 - Nyquist plot of electrochemical impedance spectra for the different stages of the 
immunosensor construction. Profiles obtained in a 0.01 mol/L Fe(CN)6
3-/4-
 solution by applying a 
frequency range from 10
-1
 to 10
5
 Hz with an amplitude perturbation of 5 mV. 
  Applying the optimized square-wave voltammetric parameters (frequency  
100 Hz, pulse amplitude 40 mV and scan increment 4 mV), calibration data were 
attained for Aβ42 concentrations ranging from 0.451 to 9028 ng/mL using two 
constructed biosensors (Figures 38-39). The analytical curve presented a wide 
concentration range (0.451 to 2257 ng/mL), linearity and low dispersion of the data, 
even at low concentrations, with high quadratic correlation coefficients of 0.998. The 
reduction of the peak current (%) depends linearly on the logarithm of Aβ42 
concentration (Figure 39). The detection limit was found to be 264 pg/mL (58 pmol/L). 
This value is lower than the previously reported ones for the detection of Aβ42 based on 
electrochemical principles [142-145]. Vestergaard et al. [142] developed a rapid label-
free electrochemical detection based on cyclic and square-wave voltammetry techniques 
for Alzheimer’s Aβ aggregation based on the study of tyrosine oxidation achieving a 
detection limit of approximately 0.7 µg/mL for Aβ40 and Aβ42. Prabhulkar et al. [143] 
developed a microbiosensor using a triple barrel carbon fiber microelectrode as the 
sensor platform. Square-wave voltammetry was used to measure the intrinsic oxidation 
signal of Aβ originated from a single tyrosine residue. This biosensor was applied to 
detection of Aβ40 and Aβ42 in mice CSF within a detection range of 20-50 nmol/L and 
20-140 nmol/L, respectively. Li et al. [144] developed an electrochemical biosensor 
using SWV for the detection of Aβ42 soluble oligomer. The peptide was immobilized in 
a mercaptoundecanoic acid SAM and levels as low as 240 pmol/L were detected. 
AuE 
MPA/AuE 
AuNPs/MPA/AuE 
Anti-Aβ42/AuNPs/MPA/AuE 
Aβ42/Anti-Aβ42/AuNPs/MPA/AuE 
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Chikae et al. [145] developed a sensor for Aβ detection with saccharide immobilized 
gold nanoparticles on carbon electrode. The detection of Aβ was performed by the 
electrochemical sensing of saccharide-protein interactions. This developed sensor had a 
detection limit of 1 µmol/L for Aβ40 and Aβ42.   
 
Figure 38 - Effect of the Aβ42 concentration (ng/mL) on the peak current (A) of the immunosensor. 
Error bars correspond to three replicates. 
 
 
Figure 39 - Analytical curve of Aβ42 obtained with the developed immunosensor. Error bars correspond 
to two replicates. 
 
The accuracy of the proposed biosensor was tested by recovery assays 
performed at two spiking levels. Recoveries of 94.6% and 96.6% were reached at the 
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fortification concentration of 903 and 451 ng/mL, respectively. The high sensitivity of 
the immunosensor can be attributed to the combination of the high performance of the 
gold electrode, versatility of the AuNPs and high affinity of the antibody-antigen 
binding. The detection of low levels of Aβ42 is fundamental for the early detection and 
monitorization of Alzheimer’s disease. In addition it also enables the determination of 
high levels of Aβ42 which is important for advanced cases of Alzheimer’s disease since 
the AD diagnostic is mainly performed by exclusion of other diseases.  
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5. Conclusion and Future directions 
In this work, an electrochemical immunosensor for Alzheimer’s disease Aβ42 
biomarker is presented. The immunosensor construction started with the testing of 
different self-assembled monolayers on the gold electrode surface. This is a simple 
technique to modify the surface of materials and to control the interface between the 
electrode and the solution. The mercaptopropionic acid SAM formation, promoted a 
large signal reduction caused by the strong adsorption of the mercaptopropionic acid on 
the gold surface hampering the electron transfer process between the electrode surface 
and the solution. Cystamine and mercaptopropionic acid + mercaptoethanol had similar 
results. 
Due to its excellent conductivity and catalytic properties, gold nanoparticles can 
act as an “electronic wire” and promote the communication between the redox centers 
in proteins and electrode surface. The catalytic activity of gold nanoparticles to amplify 
the electrochemical reactions gives them a significant priority in the design of 
electrochemical biosensors. AuNPs were electrodeposited on the SAM modified surface 
electrode and the electrical conductivity was reestablished causing a large signal 
enhancement. The next step was to immobilize the antibodies on the AuNPs. For that 
purpose, the antibodies were functionalized to promote immobilization with proper 
orientation. The quantification of Aβ42 was based on the percentage of current 
reduction of the redox pair Fe(CN)6
3-
/
4-
 caused by the specific interactions between the 
antibody and Aβ42. This label free technique exhibited analytical relevance in a wide 
concentration range (0.451 to 2257 ng/mL), with a detection limit of 264 pg/mL. The 
immunosensor accuracy was preliminary attained by recovery tests.  
The developed biosensor offers interesting possibilities for detection of the 
selected biomarker since it uses simple and relatively inexpensive instrumentation. Its 
application is intended to be cheaper, easier and faster than conventional methodologies 
while being amenable to integration for in situ determination. It constitutes a novel 
approach in AD clinical diagnosis and theragnostics because biomarker levels are 
significantly related with stage of Alzheimer’s disease.  
In future studies the repeatability and reproducibility, as well as, the stability and 
possibility of regeneration of the immunosensor should be fully characterized. In 
addition, the developed immunosensor should be tested in real samples. However before 
performing these experiments the BSA immobilization is going to be implemented in 
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order to avoid nonspecific interactions that may occur between the immunosensor and 
interfering species present in fluid samples. Also, the possibility of using a second 
labeled antibody should be tested in order to increase the sensitivity and reduce the limit 
of detection.  
Finally, characterization of the biosensor surface by scanning electron 
microscopy (SEM), transmission electron microscopy (TEM) and atomic force 
microscopy (AFM) should be performed to further confirm the SWV and EIS data. 
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